---

UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C.
20549

FORM 10-KSB

(Mark One)

[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2007

[   ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from [   ] to [  
]

Commission file number 000-51163

EUOKO GROUP INC.(Name of small business issuer in its charter)

|Nevada                                                               | 98-0547993                          
|-------------------------------------------------------------------- | ------------------------------------
|(State or other jurisdiction of incorporation or
      organization) | (I.R.S. Employer Identification No.)
|                                                                     |                                     
|67 Mowat Avenue, Suite 535                                           |                                     
|Toronto, Ontario, Canada                                             | M6K 3E3                             
|(Address of principal executive offices)                             | (Zip Code)                          

Issuer's telephone number (416) 657-3456

Securities registered pursuant to Section 12(b) of the Act:

|Title of each class | Name of each exchange on which registered
|------------------- | -----------------------------------------
|Nil                 | Nil                                      

Securities registered pursuant to Section 12(g) of the Act:

Common Shares, par value $0.001(Title of class)

Check whether the issuer (1) filed all reports required to be
filed by Section 13 or 15(d) of the Exchange Act during the past 12 months
(or for such shorter period that the registrant was required to file such
reports), and (2) has been subject to such filing requirements for the past
90 days. Yes [X]   No [   ]

Check if there is no disclosure of delinquent filers in response
to Item 405 of Regulation S-B is not contained in this form, and no
disclosure will be contained, to the best of registrant's knowledge, in
definitive proxy or information statements incorporated by reference in Part
III of this Form 10-KSB or any amendment to this Form 10-KSB. [   ]

Indicate by check mark whether the registrant is a shell company
(as defined in Rule 12-b-2 of the Exchange Act). Yes [  
]   No [X]

Issuer's revenues for its most recent fiscal year $0.00

---

The aggregate market value of the voting and non-voting common
equity held by non-affiliates:

22,841,000 common shares @ $2.1751)= $49,679,175(1)Average of bid and ask closing prices on April 11, 2008.

The number of shares outstanding of each of the issuer's classes
of equity stock, as of the latest practicable date.

35,100,000 common shares issued and outstanding as of
April 14, 2008

Large accelerated filer [   ]
      Accelerated filer                  [  
        ]Non-accelerated filer   [   ]
    Smaller reporting company [X]


Transitional Small Business Disclosure Format (Check one): Yes
[   ]   No [X]

---

PART I

Item
1.           Description of
Business.

This annual report contains forward-looking statements. These
statements relate to future events or our future financial performance. In some
cases, you can identify forward-looking statements by terminology such as may,
should,  expects, plans, anticipates, believes, estimates,
predicts, potential or continue or the negative of these terms or other
comparable terminology. These statements are only predictions and involve known
and unknown risks, uncertainties and other factors, including the risks in the
section entitled Risk Factors, that may cause our or our industrys actual
results, levels of activity, performance or achievements to be materially
different from any future results, levels of activity, performance or
achievements expressed or implied by these forward-looking statements.

Although we believe that the expectations reflected in the
forward-looking statements are reasonable, we cannot guarantee future results,
levels of activity, performance or achievements. Except as required by
applicable law, including the securities laws of the United States, we do not
intend to update any of the forward-looking statements to conform these
statements to actual results.

Our financial statements are stated in United States Dollars
(US$) and are prepared in accordance with United States Generally Accepted
Accounting Principles.

In this annual report, unless otherwise specified, all dollar
amounts are expressed in United States dollars and all references to common
shares refer to the common shares in our capital stock.

As used in this annual report, the terms we, us, our, and
Euoko mean Euoko Group Inc. and our wholly-owned subsidiaries Euoko Inc.,
Hewitt-Vevey Pharma Sciences Inc. and Vita Equity Inc., unless the context
clearly requires or states otherwise.

Corporate Overview

The address of our principal executive office is 67 Mowat
Avenue, Suite 535, Toronto, Ontario, Canada, M6K 3E3. Our telephone number is
(416) 657-3456.

Our common stock is quoted on the OTC Bulletin Board under the
symbol EUOK.

Corporate History

We were incorporated in the State of Nevada on July 25, 2000,
with an authorized capital of 50,000,000 common shares with a par value of
$0.001.

Our common shares were quoted for trading on the NASDAQs
Over-the-Counter Bulletin Board on January 30, 2006, under the symbol "VEQI".

On March 16, 2007, our board of directors approved a 2.6 for
one (1) forward stock split of our authorized, issued and outstanding shares of
common stock. The forward stock split was effective with the Secretary of State
of Nevada on March 22, 2007. As a result, our authorized capital increased from
50,000,000 shares of common stock with a par value of $0.001 to 130,000,000
shares of common stock with a par value of $0.001. Our issued and outstanding
share capital increased from 13,220,000 to 34,372,000 shares of common stock.
The forward stock split became effective with the Over-the-Counter Bulletin
Board at the opening for trading on March 22, 2007 under the stock symbol
VIEQ.

On April 5, 2007, we closed a private placement of 728,000
common shares at a purchase price of $0.235 per share for gross proceeds of
$171,080.

On May 24, 2007, we changed our name to Euoko, Inc
  pursuant to a merger with our wholly-owned subsidiary Euoko Inc., which had
  been incorporated only for the purposes of the name change. Our change of name
  became effective with the Over-the-Counter Bulletin Board at opening for trading
  on May 25, 2007 under the new stock symbol EUKO.

---

On May 31, 2007, a majority of our shareholders approved the amendment of our Articles of Incorporation to include a new class of shares. Our shareholders approved the creation of 100,000,000 preferred shares with a par value of $0.001. In
addition, shareholders gave our directors the right to fix the designations, rights, preferences or other variations of each class or series within each class of capital stock of our company. The creation of the new preferred shares was effective
with the Nevada Secretary of State on June 22, 2007.

As a result of the creation of the preferred shares, our authorized capital now consists of 130,000,000 shares of common stock with a par value of $0.001 and 100,000,000 preferred shares with a par value of $0.001.

On April 5, 2007, we entered into a letter agreement with Brandon C. Truaxe, Julio Torres and CMMG Finance Inc. to acquire all of the issued and outstanding shares of Euoko Inc., a company located in Toronto, Ontario that is engaged in the business
of the development, marketing and distribution of luxury skin treatments.

On July 23, 2007, we entered into an amended and restated share exchange agreement with Brandon C. Truaxe, Julio Torres and CMMG Finance Inc. which amends and restates the agreement entered into on April 5, 2007.

On January 10, 2008, with the approval of our board of directors, we changed our name to Euoko Group Inc. pursuant to a merger with our wholly-owned subsidiary Euoko Group Inc., which had been incorporated only for the purposes of the name change.

Our change of name became effective with the Over-the-Counter Bulletin Board at opening for trading on January 22, 2008 under the new stock symbol EUOK. Our Cusip number remained as 29841 M 103.

Subsequent Events

On March 7, 2008, we completed the share exchange with the former shareholders of Euoko Inc., Brandon C. Truaxe, Julio Alexis Torres Lopez and CMMG Finance Inc. Through this share exchange, we acquired all of the issued and outstanding shares of
Euoko Inc., a private Canadian company engaged in the business of the development, marketing and distribution of luxury skin treatments.

Although this annual report on Form 10-KSB provides the audited financial statements and related disclosure regarding the fiscal year prior to our acquisition of Euoko and our becoming engaged in the business of the development, marketing and
distribution of skin treatments, a portion of the disclosure in this report is also related to our new business: products, including our new plan of operation, risk factors, directors and officers, beneficial ownership, financial condition and
liquidity and capital resources. This has been done in order to provide accurate information and also meet the disclosure requirements of the Securities Exchange Act of 1934.

Our Current Business

We are engaged in the business of the development, marketing and distribution of skin treatments.

On December 20, 2007, we entered into and completed a share purchase agreement and acquired all of the issued and outstanding shares of Hewitt-Vevey Pharma Sciences Inc., a private Canada corporation. Hewitt-Vevey is now our wholly owned subsidiary.
Hewitt-Veveys primary business activity is intended to be the research, development, marketing and distribution of scientifically-advanced skin treatments. We intend to sell this product line through varied distribution channels in the North
American, European and Middle Eastern markets, as well as globally through an internally operated multi-currency and multi-lingual website which has yet to be developed. Although in the development stage, there are currently no products available
for distribution.

On March 7, 2008, we completed our acquisition of all of the issued and outstanding common stock of Euoko Inc., a privately held Canadian corporation, engaged in the business of the development, marketing and distribution of luxury skin treatments.
Our acquisition of this common stock was pursuant to an amended and restated share exchange agreement that we had entered into with the former shareholders of Euoko, dated effective July 23, 2007.

---

Brandon Truaxe, Julio Torres and Michael Basler have become officers of our company. For further details on our new management team, please refer to the section entitled Directors and Executive Officers.

Euoko Inc. was incorporated pursuant to the federal laws of Canada on July 16, 2003 under the name 6118356 Canada Ltd. On March 17, 2005, it changed its name to Euoko Inc. Before 2005, Euoko Inc.s primary business
activity was consulting. In 2006, Euoko Inc.s primary activity changed to the research, development, marketing and distribution of luxury skin treatments. Euoko Inc. sells its luxury skin treatment products through varied distribution channels
in select North American, European, Middle Eastern and Asian markets, as well as globally through its internally operated multi-currency and multi-lingual website.

Since the date of the share exchange, March 7, 2008, Euoko Inc. is now our wholly-owned, operating subsidiary and we have become engaged in the business of the development, marketing and distribution of luxury skin treatments. The business of Euoko
is now our business. Euoko has five product lines on the market right now: the A-Series, the P-Series, the R-Series, the W-Series and the Y-Series. Over the next 12 months, we plan to increase marketing, distribution and sales for our five product
lines and develop new products for introduction into the market.

In our current five (5) collections, we offer twenty-four (24) luxury skin treatment products: the R-Series is for enhancing skin radiance, the Y-Series is for targeting lines and wrinkles, the A-Series is for blemish-prone skin, the P-Series is for
diverse environmental protection and the W-Series is for correcting pigmentation problems. Highlights of the brands products are Intense Lift Concentrate (1 oz/30 ml for US$500), Cellular Energy Radiance Cream (1.7oz. /50ml for US$170)
and Blueprint Resculpting Cream (1.7oz. /50ml for US$180). In the next 12 months, we plan to increase marketing, distribution and sales for these five product lines and develop additional products to enhance the existing line.

Euoko's R-Series

The R-Series is formulated to restore a bright, energetic glow to the skin's appearance. The R-Series contains healthful ingredients including the worlds first pigment-balancing peptide, extracts from a wide array of marine species, exotic
fruits, African plants, a variety of biotechnologically-advanced yeast derivatives, as well as vitamins, minerals and antioxidants.

Multi-Vitamin Radiance Cleanser

This foaming cream cleanser contains plant extracts and vitamins to revive the skin, green tangerine and marine extracts to increase circulation and Swiss mountain floral extracts to regulate pigmentation.

With active principles, including Mallow, Primula Veris, Alchemilla Vulgaris, Veronica Officinalis, Melissa Officinalis Leaf and Achillea Millefolium from Switzerland, Actiphyte of Tangerine, as well as our most elite grade of Hyaluronic Acid from
Denmark.

Radiance Fluid

This super-concentrated toner increases circulation within minutes with our innovative Swiss microalgae, Dunaliella salina. Advanced peptides from France regulate pigmentation. Fig and plankton increase radiance.

With active principles, including Actiphytes of Plankton and Fig, skin-renewing Dunaliella Salina (a micro-algae) cultivated in Switzerland, a pigment-balancing Nanopeptide from France, purified derivatives of circulation-enhancing Saccharomyces
Cerevisiae, the Swiss plants Mallow, Primula Veris, Alchemilla Vulgaris, Veronica Officinalis, Melissa Officinalis Leaf and Achillea Millefolium, as well as our most elite grade of Hyaluronic Acid from Denmark.

Eye Contour Brightening Gel

Fast-acting, ultra-light gel eliminates dark circles. Clinical yeast and ellagic acid encourage concentrated circulation. Targeted peptides perfect the eye contour. Pomegranate, raspberry and grape skin extracts protect from oxidation. Plankton and
the Swiss microalga, Dunaliella salina, energize. The eye contour is left bright and merges evenly with the facial contours.

---

With active principles, including Soy and Rice Peptides, microcirculation-correcting Baker's Yeast Protein from Switzerland, multiple contour-perfecting peptides from France and Spain, a rejuvenating Protein Matrix from France, Raspberry,
Pomegranate, Grape Seed, Plankton, skin-renewing Dunaliella Salina (a micro-algae cultivated in Switzerland), antioxidant Ellagic Acid, as well as our most elite grade of Hyaluronic Acid from Denmark.

Cellular Energy Radiance Cream

This ultra-rich, creamy radiance booster is a pleasure cocktail for your senses and for your skin. Super-concentrated peptides and exclusive plant derivatives provide nourishment. Swiss microalga, Dunaliella salina, energizes the skin. The skin
glows and is infinitely more beautiful.

With active principles, including African Baobab Tree, Nanopeptides, radiance-boosting Field Dock from the Canadian Prairies, purified derivatives of circulation-enhancing Saccharomyces Cerevisiae, the Swiss plants Mallow, Primula Veris, Alchemilla
Vulgaris, Veronica Officinalis, Melissa Officinalis and Achillea Millefolium, Actiphyte of Plankton, PerfectionPeptide-P3 from Switzerland, Stabilized Vitamins A, E and C, skin-renewing Dunaliella Salina (a micro-algae) cultivated in Switzerland, as
well as Hyaluronic Acid from Denmark.

Euoko's Y-SERIES

The Y-Series is formulated for facial sculpting, lifting and smoothing treatments. Targeting every aspect of ageing, this series enjoys high concentrations of superior peptides, vitamins, amino acids, plant extracts, lipolysis enhancers (for facial
contouring), humectants and nutritive elements in an extraordinarily effective delivery system. This collection gains its confidence from superior peptides and focused derivatives, including Euoko's Okra oligo-peptides, Leuphasyl, Matrixyl 3000,
Snap-8, Argireline, Antarticine and a topical, painless facial muscle contraction inhibitor peptide that mimics the activity of the venom of the temple viper, which reflect only a brief sampling of the wide range of clinically-researched actives
used in this collection.

The Y-Series is formulated to lessen the size and number of lines and wrinkles, combat dark spots, resculpt the facial contour and restore youthful cellular energy.

Instant Precision Cellular Masque

Revive your skin instantly with this rich multi-vitamin masque with high concentrations of amazonian clay, as well as antioxidants like lycopene from tomatoes, pomegranate extract, buriti oil (richest source oil in beta-carotene) and free-radical
annihilating açaí.

With active principles, including Amazonian White Clay, rare oils of Açaí and Buriti, Soybean Oligopeptides from France, late generation liposomes of Vitamin A, stabilized Vitamin C, stabilized Vitamin E, Wheat Proteins from France,
renewing Oligosaccharides from Nopal, antioxidant Lycopene from Tomato, purified extract of Pomegranate, as well as our most elite grade of Hyaluronic Acid from Denmark.

Marine Cream Cleanser

This gentle cream cleanser provides mild exfoliation with berry fiber, as well as pomegranate and fig, while mild surfactants dissolve impurities and makeup completely. Marine derivatives and algae provide superb moisture support and enhance
collagen production for a supple skin tone.

With active principles, including a repairing Glycoprotein from the Antarctic Sea, vitamin-rich Blue Algae from the Cascadia region, Red Marine Algae from the Hawaiian Islands, antioxidant Actiphyte of Pomegranate, exfoliating Cranberry fibre, as
well as our most elite grade of Hyaluronic Acid from Denmark.

Pattern Chic

This antioxidant toner counteracts the elements with high oxy-radical absorption capacity plants and white tea.

With active principles, including extracts of Artemisia and Buddleja from the Swiss Alps, multiple biotechnologically-obtained, vitamin-rich Microalga, PerfectionPeptide-P3 from Switzerland, French Rose, Hibiscus and antioxidant Actiphytes of White
Tea, Acai Berry and Blueberry, as well as our most elite grade of Hyaluronic Acid from Denmark.

---

Intense Lift Concentrate

This ultra-concentrated cocktail of immediate and long-term fighters of lines and wrinkles is your single most important step in any anti-aging regimen. Collagen-enhancing peptides and vitamins encourage long-term plumping of the skin. White agaric
mushroom extract corrects pore size. Muscle contraction disabler peptides prevent signs of aging from occurring and relax the look of expression lines.

With active principles, including White Agaric Mushroom, Halophile Microalgae, our Swiss muscle-relaxing Tripeptide based on the science of the venom of the temple viper, advanced late-generation age-correction Polypeptides from Spain and the USA,
as well as our most elite grade of Hyaluronic Acid from Denmark.

Blueprint Resculpting Cream

This cream blends skin-tensing clinical algae, instantly-lifting polypeptides, muscle-relaxing okra oligopeptides, collagen enhancers and an array of encapsulated vitamins and protective nutrition in a luxurious, lush texture.

With active principles, including Okra Oligopeptides from France, a purified biotechnological extract of Microalga Nannochloropsis Oculata cultivated in Switzerland, expandable spheres of Hyaluronic Acid for immediate line correction, an expert
selection of multiple age-correcting Peptides including Serilesine from Spain, Matrixyl 3000 and Dermican from France, and Syn-Coll from Switzerland, as well as our most elite grade of Hyaluronic Acid from Denmark.

Euoko's A-Series

Deviating from the harsher formulations of many mainstream skincare lines aimed at treating blemishes, our A-Series makes no use of Benzoyl Peroxide, Oxygen Peroxide or industrial antimicrobial agents, most of which we believe to be carcinogenic and
are associated with abnormal oxidation of the skin. Further, our A-Series does not rely on the traditional approach of depleting the oil content of the skin's surface to eliminate blemishes. This approach often causes the skin to overproduce oil in
compensation, making the condition actually appear worse. The targeted products in the A-Series rely on the anti-bacterial super-power of multiple sesame and marine-based sebum regulating agents, as well as antibacterial oligo-peptides derived from
nature, which have been shown to deliver blemish-free skin.

Matte Foam

This ultra-foaming, gentle cleanser is designed to dissolve impurities while leaving a super matte finish on the skin. Sebum controlling agents and antibacterial marine derivatives provide anti-blemish support throughout the day.

With active ingredients, including antimicrobial Marine Derivatives from Switzerland, Naturally-Occurring Salicylic Acid, multi-fruit Acid Complex (for pore-clearing), sebum-regulating Soybean derivatives, purified Tea Tree derivatives,
blemish-correcting Actiphyte of Cranberry, as well as Hyaluronic Acid from Denmark.

Matte Water

Designed to reduce pore size, help pores breathe and restore the skins natural cycle, this toner includes meadowsweet, coneflower, Nori, distilled witch hazel and Hyaluronic Acid from Denmark.

With active principles, including Meadowsweet, Salicylic Acid, Hydrocotyl, Witch Hazel derivatives, Coneflower, Nori, as well as our most elite grade of Hyaluronic Acid from Denmark.

Matte Moisture

This moisturizer is formulated to fight acne-causing bacteria from the skins surface with a multi-faceted approach against acne. Sesame derivatives encourage proper oil balance, oligopeptides open up pores, antibacterial agents fight certain
blemishes, while traditional cranberry and tea tree extracts discourage new blemish development.

With active ingredients, including sebum-regulating Sesame, Argania Spinosa Kernel and Serenoa Serrulata Fruit from Switzerland, Triple Vitamin A Complex, Cranberry and Tea Tree derivatives, a highly purified derivative of Meadowsweet (Spiraea
Ulmaria) from France, as well as Hyaluronic Acid from Denmark.

---

Euoko's P-SERIES

Exposure to environmental aggressions such as chemicals, stress, UV radiation, dietary imbalance and pollution degrades the skin's capacity to protect itself and impedes the skin's ability to renew and rebalance itself. Our P-Series uses ingredients
such as peptides, marine derivatives, metabolic enhancers, DNA protectors (from a purified Kalahari Watermelon), as well as antioxidants from Amazonian and Himalayan berries and is formulated to restore balanced renewal, replenish lost nutrients and
create a perfectly clean, moist environment in which the skin's repair mechanisms can function optimally.

Amazonian Berry Wash

We call it berry-dermabrasion. Rub your skin gently with a rich cocktail of antioxidant fruit fibers from Himalayan goji berries, Amazonian açaí berries, cranberries and raspberries. Our Amazonian Berry Wash is formulated with multiple
vitamins and deep-sea marine derivatives to protect skin from the elements and leave skin feeling supple, revived and protected.

With active principles, including Açaí Berries, rare Goji Berries, Actiphyte of Blueberries, Cranberry Fibre, protective compounds from micro-organisms located in deep-sea hydrothermal vents, vitamin-rich Blue Algae from the Cascadia
region, Walnut Shell Powder, as well as our most elite grade of Hyaluronic Acid from Denmark.

Marine Vitamin Fluid

Daily multi-vitamin for the skin. Encapsulated vitamins provide super nourishment. Multiple berries provide antioxidant support and protect from the elements so the skin doesnt age before its time. Deep-sea marine derivatives hydrate, revive
and perfect the skins surface.

With active principles, including Amazonian Mourera, Actiphyte of Açaí Berries, Actiphyte of Blueberries, vitamin-rich Blue Algae from the Cascadia region, protective compounds from micro-organisms located in deep-sea hydrothermal
vents, two cell-renewing types of micro-algae (Nannochlorposis Oculata and Dunaliella Salina) cultivated in Switzerland, as well as our most elite grade of Hyaluronic Acid from Denmark.

Watermelon Defense

This advanced moisturizer provides maximum protection for maximum skin life. Clinical Kalahari Desert Melon protects from collagen degradation. Açaí berry provides no-nonsense antioxidant protection. UV blockers protect from sun
damage. Our elite hyaluronic acid and fermented algae moisturize and perfect the skins surface. All in our feel-good cream-gel texture.

With active principles, including a DNA-protecting, highly-purified extract of Watermelon from the Kalahari Desert, Açaí Berries from the Amazonian Rainforest, Antioxidants Lutein (from Marigold Flowers), Lycopene (from Tomatoes) and
Alpha Lipoic Acid, Stabilized Vitamins A, E and C, latest generation UV-blocking particles from the USA, two cell-renewing types of micro-algae (Nannochlorposis Oculata and Dunaliella Salina) cultivated in Switzerland, as well as our most elite
grade of Hyaluronic Acid from Denmark.

Extreme Cellular Nutrition Masque

This ultra-hydrating nutrition masque with microorganisms from deep sea vents leaves your skin supple, moist and glowing. Plankton and algae provide comfortable tightening. Rose hip oil restores circulation. Marine vitamins protect. Canadian
Willowherb seals moisture.

With active principles, including Honey extract, a repairing Glycoprotein from the Antarctic Sea, a wide-spectrum extract of Plankton, protective compounds from micro-organisms located in deep-sea hydrothermal vents, Rose Hip Seed Oil, vitamin-rich
Blue Algae extract from the Cascadia region, a purified extract of Willowherb from Canada, a DNA-protecting, highly-purified extract of Melon from the Kalahari Desert, as well as our most elite grade of Hyaluronic Acid from Denmark.

Euoko's W-SERIES

The W-Series is a line of products designed to lighten the
  skin, lighten dark spots, correct the appearance of sporadic pigmentation problems
  and provide a more even skin tone. The products in the W-Series target overall
  skin lightening or such spot darkness as freckles, age spots and sun spots.

---

The W-Series does not use hydroquinone or kojic acid, both
  of which we consider to be unsafe, unstable, carcinogenic and banned in many
  countries. Instead, we use clinically-tested ingredients, such as our lightening
  peptide from France, Alpha Arbutin from Switzerland, Tyrostat from Canada, 1-Methylhydantoine-2-imide
  (an amino acid), Magnesium Ascorbyl Phosphate (a Vitamin C derivative), Bearberry
  Extract, Encapsulated Beta Arbutin from Spain, Mallow Extract, Primula Veris
  Extract, Alchemilla Vulgaris Extract and Veronica Officinalis Extract.

The products in the W-SERIES have light textures that are absorbed quickly into the skin. The textures and absorption capacities of these products are suitable for all skin types and tones.

Extreme White Concentrate Ampoules

This 4-Week program contains our exclusive polypeptide concentrate and encapsulated multi-actives. In a formulation previously thought impossible, 12 potent actives come together at exceptionally high concentrations for the most advanced and fastest
regimen available to depigment the skin and restore an evenly white appearance to the tone.

With active principles, including cultivated Microalga Dunaliella Salina and Alpha Arbutin from Switzerland, Encapsulated Wide-Spectrum Arbutin from Spain, Ceramide IIIA and Trans-Retinoic Acid from the USA, multiple Peptides from France, Field Dock
from the Canadian Prairies, as well as our most elite grade of Hyaluronic Acid from Denmark.

Active Starch White Masque

This rich masque brightens the skin within minutes and corrects surface imperfections with rice, soy, yeast and encapsulated vitamins.

With active principles, including Alpha Arbutin from Switzerland, Encapsulated Magnesium Ascorbyl Phosphate (a most stable form of Vitamin C) from Spain, Japanese Rice Starch, Saccharomyces Cerevisiae from France and our most elite grade of
Hyaluronic Acid from Denmark.

White Foam

This richly-foaming cream cleanser brightens the skin instantly with Swiss plants and Vitamin C, while inhibiting the alpha-MSH signal for a whiter skin appearance.

With active principles, including the purest grade of Magnesium Ascorbyl Phosphate (a highly stable form of Vitamin C), Actiphyte of Bearberry, Vitamin E, the Swiss plants Mallow, Achillea Millefolium and other pigment-fighting herbs from mountains
of Switzerland, as well as our most elite grade of Hyaluronic Acid from Denmark.

Multi-Active White Water

Vitamin C and biotechnologically-produced peptides from France
  come together in this concentrated skin toner to prepare the skin for effective
  absorption of other whitening treatments.

With active principles, including Nanopeptides from France, the purest grade of Magnesium Ascorbyl Phosphate (a highly stable form of Vitamin C), Scutellaria, White Mulberry, Saxifrage, Grape, as well as our most elite grade of Hyaluronic Acid from
Denmark.

Intense White Serum

This concentrated formula brings depigmenting powers of nine effective modern active principles, including peptides, plant extracts, Alpha Arbutin and alpha-MSH blockers for an unmistakably white tone.

With active principles, including cultivated Microalga Dunaliella Salina and Alpha Arbutin from Switzerland, multiple Peptides from France, Field Dock from the Canadian Prairies, as well as our most elite grade of Hyaluronic Acid from Denmark.

---

White Moisture

With active ingredients, including Alpha Arbutin from Switzerland, Nanopeptides from France, a highly purified Melon extract from the Kalahari Desert, latest generation UV-blocking particles from the USA, as well as Hyaluronic Acid from Denmark.

Speed Control

Concentrated plant acids come together with high levels of Vitamins A and C to speed skin turnover, while advanced peptides from France enhance the action of other products.

With active ingredients, including Vitamin A in the form of Retinol Cylaspheres from the USA, Multiple Peptides from France, Mixed Acids from Tropical Fruits and Hyaluronic Acid from Denmark.

Body White Gel

This formula brings depigmenting powers of such modern active principles as peptides, Alpha Arbutin and encapsulated lightening actives for an unmistakably white tone in larger areas of the body.

With active principles, including Alpha Arbutin from Switzerland, multiple Peptides from France, 1-Methylhydantoin-2-Imide (an amino acid), Field Dock from the Canadian Prairies and Hyaluronic Acid from Denmark.

Distribution Methods Of Our Products Or Services

We distribute our Euoko products with premier retailers in at least ten countries. Currently, we have partnered with such retailers as Bergdorf Goodman in the U.S.A., Printemps in France, House of Fraser in the United Kingdom and La Rinascente in
Italy. We have also appointed key distributors in Spain, Germany, France, United Arab Emirates and China. In addition to our distributors and retail partners, we also sell our Euoko product line globally via our multi-lingual, multi-currency website
at www.euoko.com.

We plan to distribute our Hewitt-Vevey products through major retailers, shopping channels and distributors. In addition, we plan to sell our Hewitt-Vevey product line globally via an internally operated multi-lingual, multi-currency website which
has yet to be developed.

We seek to attract and retain customers by emphasizing the following key factors:

PRODUCTS - We provide consumers with skincare products that contain what we believe to be most suitable, effective ingredients for the issue targeted by each product. Our current portfolio uses more than one hundred and twenty (120) active
ingredients from around the world in the highest concentrations possible. Additionally, our exclusive marine absorption base uses a shoreline red algae and a pure grade of hyaluronic acid to maximize penetration and absorption of our active
ingredients.

SUPERIOR SHOPPING EXPERIENCE  Our retail partners are well trained and, in many cases, we employ the representatives who work at these channels. This control over the level of training offers our customers useful advice, making customer
education a key approach in attracting and maintaining customers. Further, we believe that we provide an intuitive, easy-to-use website, offering product selection supported by useful product information and clinical summary data. Offering global
exclusive points of sale, online shopping and 24-hour worldwide telephone ordering, as well as support, we guarantee a convenient and pleasant shopping experience for our customers.

GUARANTEES - We provide each customer with a four week guarantee, permitting the return of the unused product if the customer is not satisfied. We guarantee that our products are safe and effective when used as recommended. We further require that
all of our distributors and retail partners offer this guarantee to their customers.

---

Fulfillment and Distribution of Orders

We currently fulfill all customer orders from our warehousing
facilities in Canada and the United Kingdom, depending on the destination and
regulatory requirements. We are committed to shipping accurate orders,
efficiently and effectively. Generally, the delivery time is within 1 to 3
business days from the date of the receipt of the order.

Wholesale Sales

Our retail partners and distributors worldwide have access to
our proprietary software systems that allows for easy, multi-currency order
placement, payment processing, warehouse notification and administrative tasks.
Such orders are shipped from one of our international warehouse facilities
mentioned earlier for delivery within 1 to 3 business days in most cases.

Customer Service

We are dedicated to customer satisfaction. We deliver on this
commitment in a number of ways, including:

- We retain highly knowledgeable, service-oriented staff for online,
  telephone and physical retail sales, ensuring maximum customer knowledge
  transfer and support.
- We offer generous literature on our products to existing and prospective
  customers.
- We offer extensive factual advertising in exclusive print and online media,
  offering sensible product information.
- We offer multi-lingual, detailed product information on our website and via
  our 24-hour customer support telephone systems.
- We offer ample sampling opportunities  well beyond industry standards  of
  our products so that existing and prospective customers can try our products
  before committing to purchase them.
- We offer a return policy of four weeks to allow our customers to try our
  products without risk.

Technology

Our internal order processing and billing systems, customer
relationship management systems and our website have been designed for
performance, scalability and reliability. All of these internal systems are
developed by our own team of seasoned software developers using the latest
advances in technology based on Microsoft.NET.

Marketing

Euokos current marketing and advertising efforts are designed
to attract an exclusive class of customers who demand quality and clarity in
communication. Our current efforts are as follows:

- Euoko participates as a committed advertiser in more than 20 global publications
      including Town&Country (USA), Town&Country Travel (USA), Town&Country
      Weddings (USA), Surface (USA, International), New Beauty (USA), Wallpaper
      (UK, International), Nuvo (Canada), Fashion Quarterly (Canada), AnotherMagazine
      (UK, International), Vogue Italia (Italy), Beauty in Vogue (Italy), Printemps
      Magazine (France), Bergdorf Goodman Magazine (USA), as well as such industry
      publications as WWD BeautyBiz (USA) and Beauty Report International (Europe).
      In most cases, our advertising appears in every issue of our committed advertising
      base as a double-page spread.
- Euoko retains some of the top publicists, including Marcy Engelman in the
      United States. Marcy also represents such clients as Julia Roberts and has
      previously represented Lancome.
- Euoko participates in key fashion and entertainment events in various capacities.
      Historically, Euokos products have been featured in a celebrity goodie
      bag at the Academy Awards, in celebrity welcome bags at the Bryant Park
      Hotel during Fashion Week in New York and at other industry events within
      North America.

---

- Euoko is in ongoing communication with key editors worldwide, with an aggressive
    focus in the United States, Canada and the United Kingdom. Wallpaper magazine
    selected Euoko as one of the top three facial fixes of the year
    in its February 2007 Annual Design Awards issue. W Magazine is featuring a
    full-page story on Euoko in the April issue of 2008. More than twenty magazines
    and one television show have already covered Euokos products in exclusive,
    unpaid editorial content.

Competition

We expect to compete on the quality of our intellectual property (products), the concentration and breadth of our clinical active ingredients, our modern, minimalist packaging, as well as our approach to uncompromised customer service. The high
pricing of our Euoko product line positions it in the premium category whose target customer is uninfluenced by mass communication, allowing for Euoko to convey its message effectively and grow to establish itself as the authoritative brand of
quality, safety and clinical effectiveness.

While the global cosmetics market is estimated to exceed US$50B and is highly competitive, the particular niche of ultra premium skincare in which Euoko plays is currently targeted by only a select category of exclusive brands, leaving much
opportunity for quality and innovation. Euokos comparatively high pricing positions it with such key brands as La Prairie (owned by Beiersdorf), La Mer (owned by Estee Lauder Companies), SK-II (owned by Proctor and Gamble), Natura Bisse and
Amore Pacific. Euokos product portfolio employs a much larger base of active ingredients and a much higher concentration of these ingredients than all of Euokos competitors in this category. Euokos minimalist, modern packaging and
advertising approach deviates from the rich finishes and old-school approach used by its competitors, allowing Euoko to become a trend-setter in an overly modern-seeking global mindset.

We intend to sell our Hewitt-Vevey products with pricing that targets the mass consumer market and intend to bring these customers the quality of product, and concentration and breadth of clinical active ingredients currently available to the
premium category of consumers.

Intellectual Property

Despite our efforts to protect our proprietary rights, unauthorized persons may attempt to copy aspects of our website, including the look and feel of our website, products that we sell, product organization, product information and sales mechanics
or to obtain and use information that we regard as proprietary, such as the technology used to operate our website and our content. We have applied for trademark registration of Euokos key branding elements in several countries and regions,
including the United States, Canada, Europe, as well as territories in the Middle East and the Orient. Any encroachment upon our proprietary information, the unauthorized use of our trademark, the use of a similar name by a competing company or a
lawsuit initiated against us for our infringement upon another company's proprietary information or improper use of their trademark, may affect our ability to create brand name recognition, cause customer confusion and/or have a detrimental effect
on our business.

Litigation or proceedings before the U.S. Patent and Trademark Office may be necessary in the future to enforce our intellectual property rights, to protect our trade secrets and domain name and to determine the validity and scope of the proprietary
rights of others. Any litigation or adverse proceeding could result in substantial costs and diversion of resources and could seriously harm our business and operating results. Finally, as we offer and sell our products internationally, we are
impacted by the laws of many countries. The laws of many other countries do not protect our proprietary rights to as great an extent as do the laws of the United States.

Governmental Regulation

Cosmetic products are regulated by different regulatory bodies internationally. Euokos current products meet the regulatory requirements of all countries and regions in which its products are marketed. In particular, Euokos current
products meet the regulations set out in the relevant cosmetic directives in force in the members of the European Union, as well as Canada and the United States.

---

In Europe, the safety of our current products has been evaluated
  by a qualified doctor within the United Kingdom and the safety dossiers that
  discuss all products and their ingredients are housed within our United Kingdom
  office for governmental inspection as needed. This location appears on all of
  our packaging. As per regulatory requirements, we have also registered our products
  with all relevant poison control centres within the European Union.

In the United States, because our products fall within the U.S.
Food and Drug Administration's definition of "cosmetics", the two most
significant U.S. laws relating to our products are the Federal Food, Drug, and
Cosmetic Act and the Fair Packaging and Labeling Act.

The Federal Food, Drug, and Cosmetic Act prohibits the
marketing of adulterated or misbranded cosmetics in interstate commerce.
Violations of the Act involving product composition--whether they result from
ingredients, contaminants, processing, packaging, or shipping and
handling--cause cosmetics to be adulterated and subject to regulatory action.
Under the Federal Food, Drug, and Cosmetic Act, a cosmetic is adulterated if it
meets any one of the following criteria:

- it bears or contains any poisonous or deleterious substance which may
  render it injurious to users under the conditions of use prescribed in the
  labeling thereof, or under conditions of use as are customary and usual (with
  an exception made for hair dyes);
- it consists in whole or in part of any filthy, putrid, or decomposed substance;
- it has been prepared, packed, or held under unsanitary conditions whereby
  it may have become contaminated with filth, or whereby it may have been
  rendered injurious to health;
- its container is composed, in whole or in part, of any poisonous or
  deleterious substance which may render the contents injurious to health; or,
- except for hair dyes, it is, or it bears or contains, a color additive
  which is unsafe within the meaning of section 721(a) of the FD&C Act.

Improperly labeled or deceptively packaged products are
considered misbranded and subject to regulatory action. Under the Federal Food,
Drug, and Cosmetic Act, a cosmetic is considered misbranded if it meets any one
of the following criteria:

- its labeling is false or misleading in any particular;
- its label does not include all required information;
- the required information is not adequately prominent and conspicuous;
- its container is so made, formed, or filled as to be misleading;
- it is a color additive, other than a hair dye, that does not conform to
  applicable regulations issued under section 721 of the Federal Food, Drug, and
  Cosmetic Act; or,
- its packaging or labeling is in violation of an applicable regulation
  issued pursuant to section 3 or 4 of the Poison Prevention Packaging Act of
  1970.

In addition, under the authority of the Fair Packaging and
Labeling Act, the U.S. Food and Drug Administration requires an ingredient
declaration to enable consumers to make informed purchasing decisions. Cosmetics
that fail to comply with the Fair Packaging and Labeling Act are considered
misbranded under the Federal Food, Drug, and Cosmetic Act.

The U.S. Food and Drug Administration's legal authority over
  cosmetics is different from other products regulated by the agency, such as
  drugs, biologics, and medical devices. Cosmetic products and ingredients are
  not subject to the U.S. Food and Drug Administration's premarket approval authority,
  with the exception of color additives. However, the U.S. Food and Drug Administration
  may pursue enforcement action against products, firms or individuals that violate
  the applicable laws and regulations.

---

Cosmetic firms are responsible for substantiating the safety of their products and ingredients before marketing. Euokos current products meet all of FDAs regulatory requirements in effect in terms of safety, claims and labeling.

RESEARCH AND DEVELOPMENT

In the 2006 fiscal year, we spent $24,700 on research and development and in the 2007 fiscal year, we spent $70,869 on research and development. None of these costs will be borne directly by our customers.

Employees

We have twenty (20) full time employees and contractors.

RISK FACTORS

Much of the information included in this annual report includes or is based upon estimates, projections or other forward-looking statements. Such forward-looking statements include any projections or estimates made by us and our
management in connection with our business operations. While these forward-looking statements, and any assumptions upon which they are based, are made in good faith and reflect our current judgment regarding the direction of our business, actual
results will almost always vary, sometimes materially, from any estimates, predictions, projections, assumptions, or other future performance suggested herein. We undertake no obligation to update forward-looking statements to reflect events or
circumstances occurring after the date of such statements.

Such estimates, projections or other forward-looking statements involve various risks and uncertainties as outlined below. We caution readers of this annual report that important factors in some cases have affected and, in the future,
could materially affect actual results and cause actual results to differ materially from the results expressed in any such estimates, projections or other forward-looking statements. In evaluating us, our business and any investment in
our business, readers should carefully consider the following factors.

Our new business operations will be subject to a number of risks and uncertainties, including those set forth below:

Risks Related to our Company

We have a limited operating history and limited historical financial information upon which you may evaluate our performance.

We are in our early stages of development and face risks associated with a new company in a growth industry. We may not successfully address these risks and uncertainties or successfully implement our operating strategies. If we fail to do so, it
could materially harm our business to the point of having to cease operations and could impair the value of our common stock to the point investors may lose their entire investment. We may not generate positive cash flows or profits in the future.

As the majority of our business assets and all of our directors and officers are located outside of the United States; investors may be limited in their ability to enforce U.S. civil actions against our assets or our directors and officers.
You may not be able to receive compensation for damages to the value of your investment caused by wrongful actions by our directors.

The great majority of our business assets are located outside
  of the United State and all of our directors and officers are resident outside
  of the United States. Consequently, it may be difficult for investors to affect
  service of process within the United States upon our assets or our directors
  or officers, or to realize upon judgments of United States courts predicated
  upon civil liabilities under U.S. Federal Securities Laws or other laws. A judgment
  of a U.S. court predicated solely upon such civil liabilities may not be enforceable
  in other countries. You will likely not be able to recover damages as compensation
  for a decline in your investment.

---

We indemnify our officers and directors against liability to our company and our shareholders, which may reduce our directors and officers motivation to meet the standards required by law to properly carry out their duties and the
cost to us of any indemnification could negatively affect our operating results.

Our Bylaws allow for the indemnification of our officers and directors in regard to their carrying out the duties of their offices. The Bylaws also allow for reimbursement of legal defenses.

As to indemnification for liabilities arising under the Securities Act of 1933 for directors, officers or persons controlling our company, we have been informed that in the opinion of the SEC such indemnification is against public policy and
unenforceable.

Since our directors and officers are aware that they may be indemnified for carrying out the duties of their offices, they may be less motivated to meet the standards required by law to properly carry out their duties, which could have a negative
impact on our operating results. Also, if any director or officer claims against our company for indemnification, the costs could have a negative effect on our operating results.

Our management controls approximately 99.6% of the possible votes in a vote by our shareholders and their interest could conflict with the interests of investors which could cause the investor to lose all or part of the investment.

Brandon Truaxe, our President & CEO owns 10,504,000 of
  our common shares, approximately 30% of our issued and outstanding common stock,
  and 12,285,000 of our preferred shares, which is 100% of our issued and outstanding
  preferred stock. Julio Torres, our Vice President and Chief Innovations Officer,
  owns 1,755,000 of our common shares, 5% of our issued and outstanding common
  stock. Since each of our preferred shares carries the right to vote 500 times
  per preferred share, this means that Brandon Truaxe controls 6,153,004,000 votes
  out of a possible 6,177,600,000 votes, which is approximately 99.6% of the total
  possible votes in a vote by our shareholders concerning the management of our
  company. Together, Brandon Truaxe and Julio Torres control 6,154,759,000 shareholder
  votes, which is approximately 99.6% of the possible votes in a vote by our shareholders.
  Our management is able to substantially influence all matters requiring stockholder
  approval, including the election of directors and approval of significant corporate
  transactions. Such concentration of ownership may also have the effect of delaying
  or preventing a change in control, which may be to the benefit of our management
  but not in the interest of the shareholders. This beneficial ownership and potential
  effective control on all matters relating to the business and operations of
  our company could eliminate the possibility of shareholders changing the management
  in the event that the shareholders did not agree with the conduct of the officers
  and directors. Additionally, the shareholders would potentially not be able
  to obtain the necessary shareholder vote to affect any change in the course
  of business of our company. This lack of shareholder control could prevent the
  shareholders from removing from the Board of Directors any directors who are
  not managing the company with sufficient skill to make it profitable, which
  could prevent us from becoming profitable.

Risks Related to our Business

We will rely on third-party suppliers and manufacturers to provide raw materials for our products and to produce our products, and we will have limited control over these suppliers and manufacturers and may not be able to obtain quality
products on a timely basis or in sufficient quantity.

Substantially all of our products will be manufactured by unaffiliated manufacturers. We may not have any long-term contracts with our suppliers or manufacturing sources, and we expect to compete with other companies for raw materials, production
and import capacity.

There can be no assurance that there will not be a significant
  disruption in the supply of raw materials from our intended sources or, in the
  event of a disruption, that we would be able to locate alternative suppliers
  of materials of comparable quality at an acceptable price, or at all. In addition,
  we cannot be certain that our unaffiliated manufacturers will be able to fill
  our orders in a timely manner.

---

If we experience significant increased demand, or need to
  replace an existing manufacturer, there can be no assurance that additional
  supplies of raw materials or additional manufacturing capacity will be available
  when required on terms that are acceptable to us, or at all, or that any supplier
  or manufacturer would allocate sufficient capacity to us in order to meet our
  requirements. In addition, even if we are able to expand existing or find new
  manufacturing or raw material sources, we may encounter delays in production
  and added costs as a result of the time it takes to train our suppliers and
  manufacturers in our methods, products and quality control standards. Any delays,
  interruption or increased costs in the supply of raw materials or manufacture
  of our products could have an adverse effect on our ability to meet retail customer
  and consumer demand for our products and result in lower revenues and net income
  both in the short and long-term.

In addition, there can be no assurance that our suppliers and manufacturers will continue to provide raw materials and to manufacture products that are consistent with our standards. We may receive shipments of product that fail to conform to our
quality control standards. In that event, unless we are able to obtain replacement products in a timely manner, we risk the loss of revenues resulting from the inability to sell those products and related increased administrative and shipping costs.
In addition, because we do not control our manufacturers, products that fail to meet our standards or other unauthorized products could end up in the marketplace without our knowledge, which could harm our reputation in the marketplace.

Risks Related to our Securities

Our common stock may be affected by limited trading volume and may fluctuate significantly. Substantial fluctuations in our stock price could significantly reduce the price of our stock.

There has been a limited public market for our common stock and there can be no assurance an active trading market for our common stock will develop. This could adversely affect our shareholders ability to sell our common stock in short time
periods or possibly at all. Our common stock has experienced and is likely to experience significant price and volume fluctuations that could adversely affect the market price of our common stock without regard to our operating performance. Our
stock price could fluctuate significantly in the future based upon any number of factors such as: general stock market trends; announcements of developments related to our business; fluctuations in our operating results; announcements of
technological innovations, new products or enhancements by us or our competitors; general conditions in the markets we serve; general conditions in the U.S. or world economy; developments in patents or other intellectual property rights; the
performance of our eligible portfolio companies; and developments in our relationships with our customers and suppliers. Substantial fluctuations in our stock price could significantly reduce the price of our stock.

Our common stock is traded on the "Over-the-Counter Bulletin Board," which may make it more difficult for investors to resell their shares due to suitability requirements.

Our common stock is currently traded on the Over the Counter Bulletin Board (OTCBB) where we expect it to remain in the foreseeable future. Broker-dealers often decline to trade in OTCBB stocks given the market for such securities are often limited,
the stocks are more volatile, and the risk to investors is greater. These factors may reduce the potential market for our common stock by reducing the number of potential investors. This may make it more difficult for investors in our common stock
to sell shares to third parties or to otherwise dispose of their shares. This could cause our stock price to decline.

Our stock is a penny stock. Trading of our stock may be restricted by the Securities and Exchange Commissions penny stock regulations and the Financial Industry Regulatory Authoritys sales practice requirements, which may limit a
stockholder's ability to buy and sell our stock.

Our stock is a penny stock. The Securities and Exchange Commission
  has adopted Rule 15g-9 which generally defines "penny stock" to be any equity
  security that has a market price (as defined) less than $5.00 per share
  or an exercise price of less than $5.00 per share, subject to certain exceptions.
  Our securities are covered by the penny stock rules, which impose additional
  sales practice requirements on broker-dealers who sell to persons other than
  established customers and "accredited investors". The term "accredited investor"
  refers generally to institutions with assets in excess of $5,000,000 or individuals
  with a net worth in excess of $1,000,000 or annual income exceeding $200,000
  or $300,000 jointly with their spouse.

---

The penny stock rules require a broker-dealer, prior to a transaction
  in a penny stock not otherwise exempt from the rules, to deliver a standardized
  risk disclosure document in a form prepared by the Securities and Exchange Commission
  which provides information about penny stocks and the nature and level of risks
  in the penny stock market. The broker-dealer also must provide the customer
  with current bid and offer quotations for the penny stock, the compensation
  of the broker-dealer and its salesperson in the transaction and monthly account
  statements showing the market value of each penny stock held in the customer's
  account. The bid and offer quotations, and the broker-dealer and salesperson
  compensation information, must be given to the customer orally or in writing
  prior to effecting the transaction and must be given to the customer in writing
  before or with the customer's confirmation. In addition, the penny stock rules
  require that prior to a transaction in a penny stock not otherwise exempt from
  these rules, the broker-dealer must make a special written determination that
  the penny stock is a suitable investment for the purchaser and receive the purchaser's
  written agreement to the transaction. These disclosure requirements may have
  the effect of reducing the level of trading activity in the secondary market
  for the stock that is subject to these penny stock rules. Consequently, these
  penny stock rules may affect the ability of broker-dealers to trade our securities.
  We believe that the penny stock rules discourage investor interest in and limit
  the marketability of our common stock.

In addition to the "penny stock" rules promulgated by the
Securities and Exchange Commission, the Financial Industry Regulatory Authority
has adopted rules that require that in recommending an investment to a customer,
a broker-dealer must have reasonable grounds for believing that the investment
is suitable for that customer. Prior to recommending speculative low priced
securities to their non-institutional customers, broker-dealers must make
reasonable efforts to obtain information about the customer's financial status,
tax status, investment objectives and other information. Under interpretations
of these rules, the Financial Industry Regulatory Authority believes that there
is a high probability that speculative low priced securities will not be
suitable for at least some customers. The Financial Industry Regulatory
Authority requirements make it more difficult for broker-dealers to recommend
that their customers buy our common stock, which may limit your ability to buy
and sell our stock.

Item
2.           Description
of Property.

Principal Offices

We lease our main office at 67 Mowat Avenue, Suite 535,
Toronto, Ontario, Canada. This office provides us with 1,914 square feet of
space for monthly rent of CDN$4,226.75. This space currently meets all of our
needs but we may require additional or different office space over the next
twelve months to facilitate our expected staffing growth.

Item
3.           Legal
Proceedings.

We know of no material, active or pending legal proceedings
against our company, nor are we involved as a plaintiff in any material
proceeding or pending litigation. There are no proceedings in which any of our
directors, officers or affiliates, or any registered or beneficial shareholder,
is an adverse party or has a material interest adverse to our interest.

Item
4.           Submissions
of Matters to a Vote of Security Holders.

None

PART II

Item
5.           Market for
Common Equity and Related Stockholder Matters.

In the United States, our common shares are quoted on the
Over-the-Counter Bulletin Board under the symbol EUOK. The following
quotations, obtained from Yahoo Finance, reflect the high and low bids for our
common shares based on inter-dealer prices, without retail mark-up, mark-down or
commission and may not represent actual transactions.

---

Our common shares were originally quoted for trading on the
OTCBB on January 30, 2006 under the symbol VEQI.

The high and low bid prices of our common stock for the periods
indicated below are as follows:

National Association of Securities Dealers OTC Bulletin
      Board(1)Quarter Ended
    High
    LowDecember 31, 2007
    $0.95
    $0.58September 30, 2007
    $2.00
    $0.65June 30, 2007
    $2.20
    $0.85March 31, 2007
    $1.05
    $0.55December 31, 2006
    N/A(2)
    N/A(2)September 30, 2006
    N/A(2)
    N/A(2)June 30, 2006
    $0.11
    $0.11March 31, 2006
    N/A(3)
    N/A(3)


(1) Over-the-counter market quotations
reflect inter-dealer prices without retail mark-up, mark-down or commission, and
may not represent actual transactions.

(2) No trades occurred during this
period.

(3) Our first trade did not occur
until June 15, 2006.

Our common shares are issued in registered form. Holladay Stock
Transfer Inc., 2939 N. 67th Street, Scottsdale, AZ 85251 (Telephone: (480)
481-3940.; Facsimile: (480) 481-3941) is the registrar and transfer agent for
our common shares.

On April 14, 2008, the shareholders' list of our common shares
showed 14 registered shareholders, 35,100,000 common shares and 12,285,000
preferred shares outstanding.

Dividend Policy

We have not paid any cash dividends on our common stock and
have no present intention of paying any dividends on the shares of our common
stock. Our current policy is to retain earnings, if any, for use in our
operations and in the development of our business. Our future dividend policy
will be determined from time to time by our board of directors.

Recent Sales of Unregistered Securities

During the fiscal year ended December 31, 2007

On April 5, 2007, we closed a private placement of 728,000
common shares at a purchase price of $0.235 per share for gross proceeds of
$171,080. We conducted the private placement in an offshore transaction relying
on Rule 903 of Regulation S of the Securities Act of 1933. None of the
subscribers were U.S. persons, as defined in Regulation S. No directed selling
efforts were made in the United States by Euoko Group, any distributor, any of
their respective affiliates or any person acting on behalf of any of the
foregoing. We implemented the applicable offering restrictions required by Rule
903 of Regulation S by including a legend on all offering materials and
documents which stated that the shares have not been registered under the
Securities Act of 1933 and may not be offered or sold in the United States or to
US persons unless the shares are registered under the Securities Act of 1933, or
an exemption from the registration requirements of the Securities Act of 1933 is
available. The offering materials and documents also contain a statement that
hedging transactions involving the shares may not be conducted unless in
compliance with the Securities Act of 1933.

---

Subsequent to the fiscal year ended December 31, 2007

On March 7, 2008, we issued 12,285,000 shares of our preferred
stock to one (1) investor pursuant to an amended and restated share exchange
agreement with Euoko Inc. as partial consideration for all of the issued and
outstanding shares of Euoko Inc. We issued the preferred shares to one (1)
non-U.S. person (as that term is defined in Regulation S of the Securities Act
of 1933), in an offshore transaction relying on an exemption from registration
under Regulation S and/or Section 4(2) of the Securities Act of 1933. No
directed selling efforts were made in the United States by Euoko Group, any
distributor, any of their respective affiliates or any person acting on behalf
of any of the foregoing. We implemented the applicable offering restrictions
required by Rule 903 of Regulation S by including a legend on all offering
materials and documents which stated that the shares have not been registered
under the Securities Act of 1933 and may not be offered or sold in the United
States or to US persons unless the shares are registered under the Securities
Act of 1933, or an exemption from the registration requirements of the
Securities Act of 1933 is available. The offering materials and documents also
contain a statement that hedging transactions involving the shares may not be
conducted unless in compliance with the Securities Act of 1933.

On March 7, 2008, we granted common stock options to 14 of our
employees, consultants, officers and directors to purchase an aggregate of
1,500,000 shares of our common stock at an exercise price of $1.00 per share,
exercisable until March 7, 2013. We granted these options pursuant to an amended
and restated share exchange agreement with Euoko Inc. as partial consideration
for all of the issued and outstanding shares of Euoko Inc. We granted 1,450,000
of the common stock options to thirteen (13) non-U.S. persons (as that term is
defined in Regulation S of the Securities Act of 1933), in an offshore
transaction relying on Regulation S and/or Section 4(2) of the Securities Act of
1933. No directed selling efforts were made in the United States by Euoko Group,
any distributor, any of their respective affiliates or any person acting on
behalf of any of the foregoing. We implemented the applicable offering
restrictions required by Rule 903 of Regulation S by including a legend on all
offering materials and documents which stated that the shares have not been
registered under the Securities Act of 1933 and may not be offered or sold in
the United States or to US persons unless the shares are registered under the
Securities Act of 1933, or an exemption from the registration requirements of
the Securities Act of 1933 is available. The offering materials and documents
also contain a statement that hedging transactions involving the shares may not
be conducted unless in compliance with the Securities Act of 1933. We granted
50,000 of the common stock options to one (1) U.S. person (as that term is
defined in Regulation S of the Securities Act of 1933), in reliance on
Regulation D and/or Section 4(2) of the Securities Act of 1933.

Equity Compensation Plan Information

We have not adopted any equity compensation plans.

Item
6.           Plan of
Operation.

Overview

You should read the following discussion of our financial
condition and results of operations together with the audited financial
statements and the notes to audited financial statements included elsewhere in
this filing prepared in accordance with accounting principles generally accepted
in the United States. This discussion contains forward-looking statements that
reflect our plans, estimates and beliefs. Our actual results could differ
materially from those anticipated in these forward-looking statements.

Plan of Operations

Over the next twelve month period we intend to pursue our
business plan of developing, marketing and distributing luxury skin treatments.
We also intend to develop, market and distribute a line of skin treatments
through our subsidiary Hewitt-Vevey. We intend to explore ways of expanding our
company through greater marketing, sales and distribution arrangements. We may
have to raise additional financing to be able to take advantage of expansion
opportunities as they arise. If we do require additional financing, we will
likely do that through taking on debt and we may consider the sale of equity
securities. We have not determined which, if any, expansion opportunities we
will proceed with but we would like to have the financing to be ready to act
quickly if the right opportunity arises.

---

Over the next twelve months, we also plan to continue our
current research and development work on ten new products. We hope to have
completed products ready to introduce to the market by end of 2008. Seven of the
ten products we are working on are for our Euoko line and three are for our
Hewitt-Vevey subsidiary.

Product Research and Development

We anticipate that we will expend $250,000 on research and
development over the twelve months ending December 31, 2008.

Purchase of Significant Equipment

We do not intend to purchase any significant equipment over the
twelve months ending December 31, 2008.

Employees

We have twenty (20) full time employees and contractors.

Financial Condition, Liquidity and Capital Resources

Our principal capital resources have been through the issuance
of common stock, shareholder loans and advances from related parties.

As of December 31, 2007, our total assets were $100,498
compared to total assets of $708,595 as of December 31, 2006. This decrease was
due to the fact that we stopped carrying out our former business.

As of December 31, 2007 our total current liabilities were
$52,395 as compared to $699,433 as of December 31, 2006. This decrease was due
to the fact that we stopped carrying out our former business.

As of December 31, 2007 we had cash in the amount of $35,195
compared to cash in the amount of $10,943 as of December 31, 2006. This increase
was due to the fact that we closed a private placement of 728,000 common shares
at a purchase price of $0.235 per share for gross proceeds of $171,080.

Cash Requirements

As of April 9, 2008, we had cash on hand of $85,000. Management
projects that we may require an additional $3,165,000 to fund our ongoing
operating expenditures, offering expenses and working capital requirements for
the twelve month period ending December 31, 2008, broken down as follows:

Estimated Funding Required During the Twelve Month Period Ending
December 31, 2008

Operating expendituresMarketing & Sales
    $1,750,000General and Administrative
    $750,000Product development and deployment
    $400,000Working capital
    $350,000Total (including Offering Costs)
    $3,250,000


As at January 1, 2008, we had available funding totaling $1,050,000
  under a term loan agreement with a related party and on April 14, 2008 this
  facility was increased by $1,500,000. In addition, on March 7, 2008, our Hewitt-Vevey
  subsidiary entered into a term loan agreement with a related party totaling
  $1,150,000. This agreement is attached hereto as an exhibit. This funding should
  allow us to meet our current cash requirements. We may have to raise additional
  monies through private placements of our equity securities and/or debt financing
  in order that we may fund continuing operational expenses beyond this twelve-month
  period.

---

Due to the uncertainty of our ability to generate a sustainable
  operation, in their report on the annual financial statements for the year ended
  December 31, 2007, our independent auditors included an explanatory paragraph
  regarding concerns about our ability to continue as a going concern. Our financial
  statements contain additional note disclosures describing the circumstances
  that lead to this disclosure by our independent auditors.

There are no assurances that we will be able to obtain further funds as may be required for our continued operations. If required, we will pursue various financing alternatives to meet our immediate and long-term financial requirements, which we
anticipate will consist of further private placements of equity securities, advances from related parties or shareholder loans. We have not entered into any definitive agreements with any shareholders or related parties for the provision of loans or
advances. There can be no assurance that additional financing will be available to us when needed or, if available, that it can be obtained on commercially reasonable terms. If we are not able to obtain the additional financing on a timely basis, we
will not be able to meet our other obligations as they become due and we will be forced to scale down or perhaps even cease our operations.

Going Concern

We have historically incurred losses and have incurred a net loss of $133,593 for the year ended December 31, 2007. Because of these historical losses, we will require additional working capital to develop our business operations. We intend to
raise additional working capital through private placements, public offerings, bank financing and/or advances from related parties or shareholder loans.

The continuation of our business is dependent upon obtaining further financing and achieving a break even or profitable level of operations. The issuance of additional equity securities by us could result in a significant dilution in the equity
interests of our current or future stockholders. Obtaining commercial loans, assuming those loans would be available, will increase our liabilities and future cash commitments.

There are no assurances that we will be able to either (i) achieve a level of revenues adequate to generate sufficient cash flow from operations; or (ii) obtain additional financing through either private placements, public offerings and/or bank
financing necessary to support our working capital requirements. To the extent that funds generated from operations and any private placements, public offerings and/or bank financing are insufficient, we will have to raise additional working
capital. No assurance can be given that additional financing will be available, or if available, will be on terms acceptable to us. If adequate working capital is not available we may not increase our operations.

These conditions raise substantial doubt about our ability to continue as a going concern. The financial statements do not include any adjustments relating to the recoverability and classification of asset carrying amounts or the amount and
classification of liabilities that might be necessary should we be unable to continue as a going concern.

APPLICATION OF CRITICAL ACCOUNTING POLICIES

Our financial statements and accompanying notes are prepared in accordance with generally accepted accounting principles in the United States. Preparing financial statements requires management to make estimates and assumptions that affect the
reported amounts of assets, liabilities, revenue, and expenses. These estimates and assumptions are affected by managements application of accounting policies. We believe that understanding the basis and nature of the estimates and assumptions
involved with the following aspects of our financial statements is critical to an understanding of our financials.

In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent
assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates.

Critical Accounting Policies

In December 2001, the SEC requested that all registrants list
  their three to five most critical accounting polices in the Management
  Discussion and Analysis. The SEC indicated that a critical accounting
  policy is one which is both important to the portrayal of a companys
  financial condition and results, and requires managements most difficult,
  subjective or complex judgments, often as a result of the need to make estimates
  about the effect of matters that are inherently uncertain. We believe that the
  following accounting policies fit this definition.

---

Revenue Recognition

Product sales are reported on a net basis, which is computed by deducting from gross sales discounts, the amount of actual product returns received and an amount estimated for anticipated product returns. Product sales are recognized upon the
passage of title to the customer, provided that the collection of the proceeds from sales is reasonably assured. The Companys practice is to accept product returns within four weeks of shipment to the customer, only if properly requested, for
a full refund less a nominal return shipping charge

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and
disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these estimates.

Foreign currency translation

Assets and liabilities of the foreign subsidiary are translated into U.S. dollars at period end exchange rates. Capital accounts are translated into U.S. dollars at the acquisition date rates. Income and expense items are translated at the weighted
average exchange rates for the period. Net exchange gains or losses resulting from such translations are excluded from net income (loss) but are included in comprehensive income (loss) and accumulated in a separate component of stockholders' equity.

Recently Issued Accounting Pronouncements

In September 2006, the Financial Accounting Standards Board (FASB) issued SFAS No. 157, "Fair Value Measurements," which provides enhanced guidance for using fair value to measure assets and liabilities. SFAS No. 157 provides a common
definition of fair value and establishes a framework to make the measurement of fair value in generally accepted accounting principles more consistent and comparable. SFAS No. 157 also requires expanded disclosures to provide information about the
extent to which fair value is used to measure assets and liabilities, the methods and assumptions used to measure fair value, and the effect of fair value measures on earnings. SFAS No. 157 is effective for financial statements issued in fiscal
years beginning after November 15, 2007 and to interim periods within those fiscal years.

In February 2007, the FASB issued SFAS Statement No. 159, The Fair Value Option for Financial Assets and Financial Liabilities  Including an amendment of FASB Statement No. 115 (SFAS 159). SFAS 159, which becomes effective for the
Company on January 1, 2008, permits companies to choose to measure many financial instruments and certain other items at fair value and report unrealized gains and losses in earnings. Such accounting is optional and is generally to be applied
instrument by instrument.

In December 2007, the FASB issued FASB Statement No. 141 (R), Business Combinations (FAS 141(R)), which establishes accounting principles and disclosure requirements for all transactions in which a company obtains control over another
business. Statement 141 (R) applies prospectively to business combinations for which the acquisition date is on or after the beginning of the first annual reporting period beginning on or after December 15, 2008. Earlier adoption is prohibited.

In December 2007, the FASB issued SFAS No. 160, Noncontrolling Interests in Consolidated Financial Statements, an amendment of ARB No. 51. SFAS No. 160 establishes accounting and reporting standards that require that the ownership
interests in subsidiaries held by parties other than the parent be clearly identified, labeled, and presented in the consolidated statement of financial position within equity, but separate from the parents equity; the amount of consolidated
net income attributable to the parent and to the noncontrolling interest be clearly identified and presented on the face of the consolidated statement of income; and changes in a parents ownership interest while the parent retains its
controlling financial interest in its subsidiary be accounted for consistently.

---

SFAS No. 160 also requires that any retained noncontrolling
equity investment in the former subsidiary be initially measured at fair value
when a subsidiary is deconsolidated. SFAS No. 160 also sets forth the disclosure
requirements to identify and distinguish between the interests of the parent and
the interests of the noncontrolling owners. SFAS No. 160 applies to all entities
that prepare consolidated financial statements, except not-for-profit
organizations, but will affect only those entities that have an outstanding
noncontrolling interest in one or more subsidiaries or that deconsolidate a
subsidiary. SFAS No. 160 is effective for fiscal years, and interim periods
within those fiscal years, beginning on or after December 15, 2008. Earlier
adoption is prohibited. SFAS No. 160 must be applied prospectively as of the
beginning of the fiscal year in which it is initially applied, except for the
presentation and disclosure requirements. The presentation and disclosure
requirements are applied retrospectively for all periods presented.

The Company does not believe that the adoption of the above
recent pronouncements will have a material effect on the Companys consolidated
results of operations, financial position, or cash flows.

Item
7.           Financial
Statements.

Our financial statements are stated in United States dollars
(US$) and are prepared in accordance with United States Generally Accepted
Accounting Principles.

On March 7, 2008, we acquired Euoko Inc., a private Canadian
Corporation, and became engaged in the business of the development, marketing
and distribution of luxury skin treatments. Our financial statements filed in
this annual report reflect periods that ended prior to our acquisition of Euoko
Inc.

The following consolidated financial statements are filed as
part of this annual report:

|Report
      of Independent Registered Public Accounting Firm, dated April 12, 2008                                                                                    
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------
|                                                                                                                                                                       
|Audited
      Consolidated Balance Sheets as of December 31, 2007 and December 31, 2006                                                                                
|                                                                                                                                                                       
|Audited
      Consolidated Statements of Operations and Comprehensive Income (Loss) for
      the year ended December 31, 2007 and for the year ended December 31, 2006
|                                                                                                                                                                       
|Audited
      Consolidated Statements of Cash Flows for the year ended December 31, 2007
      and for the year ended December 31, 2006                                
|                                                                                                                                                                       
|Audited
      Consolidated Statements of Changes in Stockholders' Equity for year ended
      December 31, 2007 and for the year ended December 31, 2006               
|                                                                                                                                                                       
|Notes
      to the Consolidated Financial Statements                                                                                                                   

---





EUOKO GROUP INC. (formerly VITA EQUITY INC.) AND SUBSIDIARY
  
  CONSOLIDATED FINANCIAL STATEMENTSAS OF DECEMBER 31, 2007 AND 2006





F-1

---

EUOKO GROUP INC. (formerly VITA EQUITY INC.) AND SUBSIDIARY



CONTENTS

PAGE
      1
      REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRMPAGE
      2
      CONSOLIDATED BALANCE SHEETS AS OF DECEMBER 31, 2007 AND
          2006PAGE
      3
      CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE
          INCOME (LOSS) FOR THE YEARS ENDED DECEMBER 31, 2007 AND 2006PAGE
      4
      CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY FOR
          THE YEARS ENDED DECEMBER 31, 2007 AND 2006PAGE
      5
      CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED
          DECEMBER 31, 2007 AND 2006PAGE
      6-15
      NOTES TO CONSOLIDATED FINANCIAL STATEMENTS AS OF DECEMBER
          31, 2007 AND 2006 F-2


---

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Stockholders of 
  Euoko Group Inc. (formerly Vita Equity Inc.) and Subsidiary

We have audited the accompanying consolidated balance sheets
  of Euoko Group Inc. (formerly Vita Equity Inc.) and Subsidiary as of December
  31, 2007 and 2006 and the related consolidated statements of operations and
  comprehensive income (loss), stockholders’ equity and cash flows for the
  years then ended. These consolidated financial statements are the responsibility
  of the Company's management. Our responsibility is to express an opinion on
  these consolidated financial statements based on our audits.

We conducted our audits in accordance with standards of the Public
  Company Accounting Oversight Board (United States). Those standards require
  that we plan and perform the audits to obtain reasonable assurance whether the
  consolidated financial statements are free of material misstatement. The Company
  is not required to have, nor were we engaged to perform, an audit of its internal
  control over financial reporting. Our audit included consideration of internal
  control over financial reporting as a basis for designing audit procedures that
  are appropriate in the circumstances, but not for the purpose of expressing
  an opinion on the effectiveness of the Companys internal control over
  financial reporting. Accordingly, we express no such opinion. An audit includes
  examining, on a test basis, evidence supporting the amounts and disclosures
  in the consolidated financial statements. An audit also includes assessing the
  accounting principles used and significant estimates made by management, as
  well as evaluating the overall financial statement presentation. We believe
  that our audits provide a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred
  to above present fairly, in all material respects, the financial position of
  Euoko Group Inc. (formerly Vita Equity Inc.) and Subsidiary as at December 31,
  2007 and 2006 and the results of their operations and their cash flows for the
  years then ended, in conformity with accounting principles generally accepted
  in the United States of America.

The accompanying consolidated financial statements have been
  prepared assuming that the Company will continue as a going concern. As discussed
  in Note 1 to the consolidated financial statements, the Company has no sustainable
  operations and had an accumulated deficit of $147,381 as of December 31, 2007.
  These matters raise substantial doubt about its ability to continue as a going
  concern. Managements plans in regard to these matters are also described
  in Note 1. The consolidated financial statements do not include any adjustments
  that might result from the outcome of this uncertainty.

As discussed in Note 1 to the consolidated financial statements,
  on March 7, 2008, the Company acquired all of the outstanding shares of Euoko
  Inc. (Canada), a private Canadian company in exchange for $145,000 and 12,285,000
  shares of preferred stock and as a result Euoko Inc. (Canada) became a wholly
  owned subsidiary of the Company. The acquisition was accounted for as a reverse
  merger (recapitalization) with Euoko, Inc. (Canada) deemed to be the accounting
  acquirer, and the Company the legal acquirer.

Weinberg & Company, P.A. 
  Los Angeles, California 
  April 12, 2008

F-3

---

EUOKO GROUP INC. (formerly VITA EQUITY INC.) AND SUBSIDIARY
  
  CONSOLIDATED BALANCE SHEETS

|ASSETS                                                              |  
|------------------------------------------------------------------- | -
|                                                                    |  
|                                                                    |  
|                                                                    |  
|                                                                    |  
|CURRENT ASSETS                                                      |  
|Cash                                                                | $
|Sales tax receivable                                                |  
|Prepaid expenses                                                    |  
|                                                                    |  
|Assets related to discontinued operations:                          |  
|Accounts receivable,
      trade                                    |  
|Accounts receivable, related party                                  |  
|Total Current
      Assets                                          |  
|                                                                    |  
|Goodwill                                                            |  
|                                                                    |  
|Total Assets                                                        | $
|                                                                    |  
|                                                                    |  
|LIABILITIES AND STOCKHOLDERS EQUITY                                |  
|                                                                    |  
|CURRENT LIABILITIES                                                 |  
|Accounts payable and accrued liabilities                            | $
|Due to stockholder                                                  |  
|                                                                    |  
|LIABILITIES RELATED TO DISCONTINUED OPERATIONS,                     |  
|Accounts payable                                                    |  
|                                                                    |  
|Total liabilities                                                   |  
|                                                                    |  
|COMMITMENTS AND CONTINGENCIES                                       |  
|                                                                    |  
|STOCKHOLDERS EQUITY                                                |  
|Preferred stock, $.001
      par value, 100,000,000 shares          |  
|authorized,
      no shares issued and outstanding                  |  
|Common stock, $.001
      par value, 130,000,000 shares authorized, |  
|35,100,000
      and 34,372,000 shares issued and outstanding at    |  
|December 31, 2007
      and 2006,respectively                       |  
|Additional
      paid in capital                                    |  
|Accumulated Deficit                                                 |  
|Accumulated
      other comprehensive income                        |  
|Total stockholders
      equity                                    |  
|                                                                    |  
|Total liabilities and stockholders equity                          | $

See accompanying notes to consolidated financial statements. 
  F-4

---

EUOKO GROUP INC. (formerly VITA EQUITY INC.) AND SUBSIDIARY
  
  CONSOLIDATED STATEMENTS OF OPERATIONSAND COMPREHENSIVE INCOME (LOSS) 
  FOR THE YEARS ENDED DECEMBER 31, 2007 AND 2006

|                                                                           |   | December 31, |   |   | December 31, |  
|-------------------------------------------------------------------------- | - | ------------ | - | - | ------------ | -
|                                                                           |   | 2007         |   |   | 2006         |  
|                                                                           |   |              |   |   |              |  
|Revenues                                                                   | $ | -            |   | $ | -            |  
|                                                                           |   |              |   |   |              |  
|Operating expenses                                                         |   | 124,988      |   |   | 27,015       |  
|                                                                           |   |              |   |   |              |  
|Loss from continuing operations                                            |   | (124,988     | ) |   | (27,015      | )
|                                                                           |   |              |   |   |              |  
|Income (loss) from discontinued operations                                 |   | (8,605       | ) |   | 27,627       |  
|                                                                           |   |              |   |   |              |  
|Net income (loss)                                                          |   | (133,593     | ) |   | 612          |  
|                                                                           |   |              |   |   |              |  
|Other comprehensive income, foreign currency
      translation adjustments |   | 1,454        |   |   | 847          |  
|                                                                           |   |              |   |   |              |  
|Comprehensive (loss) income                                                | $ | (132,139     | ) | $ | 1,459        |  
|                                                                           |   |              |   |   |              |  
|Loss from continuing operations per common
      share, basic and diluted  | $ | -            |   | $ | -            |  
|(Loss) income from discontinued operations per common share,
      basic   |   |              |   |   |              |  
|and diluted                                                                | $ | -            |   | $ | -            |  
|Net (loss) income per common share, basic and diluted                      | $ | -            |   | $ | -            |  
|                                                                           |   |              |   |   |              |  
|                                                                           |   |              |   |   |              |  
|Weighted average shares outstanding, basic and diluted                     |   | 34,910,521   |   |   | 34,372,000   |  

See accompanying notes to consolidated financial statements. 
  F-5

---

EUOKOGROUPINC(formerlyVITAEQUITYINC.) ANDSUBSIDIARYCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYFOR THEYEARSENDEDDECEMBER31, 2007 AND 2006

AccumulatedCommon
      
      
      Additional
      
      
      
      
      
      OtherCommon
      
      
      Stock
      
      
      Paid in
      
      
      Accumulated
      
      
      ComprehensiveStock
      
      
      Amount
      
      
      Capital
      
      
      Deficit
      
      
      Income
      
      
      TotalBALANCE, JANUARY 1, 2006
      
      34,372,000
      
      $
      34,372
      
      $
      (21,152
      )
      $
      (14,400
      )
      $
      8,883
      
      $
      7,703Foreign currency translation gain
      
      -
      
      
      -
      
      
      -
      
      
      -
      
      
      847
      
      
      847Net income
      
      -
      
      
      -
      
      
      -
      
      
      612
      
      
      -
      
      
      612BALANCE, DECEMBER 31, 2006
      
      34,372,000
      
      
      34,372
      
      
      (21,152
      )
      
      (13,788
      )
      
      9,730
      
      
      9,162Issuance of shares in private placement
      
      728,000
      
      
      728
      
      
      170,352
      
      
      -
      
      
      -
      
      
      171,080Foreign currency translation gain
      
      -
      
      
      -
      
      
      -
      
      
      -
      
      
      1,454
      
      
      1,454Net loss
      
      -
      
      
      -
      
      
      -
      
      
      (133,593
      )
      
      -
      
      
      (133,593
      )BALANCE, DECEMBER 31, 2007
      
      35,100,000
      
      $
      35,100
      
      $
      149,200
      
      $
      (147,381
      )
      $
      11,184
      
      $
      48,103


See accompanying notes to consolidated financial statements.
  F-6

---

EUOKO GROUP INC (formerly VITA EQUITY INC.) AND SUBSIDIARY
  
  CONSOLIDATED STATEMENTS OF CASH FLOWSFOR THE YEARS ENDED DECEMBER 31, 2007 AND 2006

|                                                                          |   | December 31, |   |   | December 31, |  
|------------------------------------------------------------------------- | - | ------------ | - | - | ------------ | -
|                                                                          |   | 2007         |   |   | 2006         |  
|CASH FLOWS FROM OPERATING ACTIVITIES:                                     |   |              |   |   |              |  
|Net (loss) income                                                         | $ | (133,593     | ) | $ | 612          |  
|Adjustments to reconcile net (loss) income
      to net cash (used in)    |   |              |   |   |              |  
|provided by operating activities:                                         |   |              |   |   |              |  
|(Loss) income from discontinued operations                                |   | (8,605       | ) |   | 27,627       |  
|                                                                          |   |              |   |   |              |  
|Changes in operating assets and liabilities:                              |   |              |   |   |              |  
|Sales tax receivable                                                      |   | (216         | ) |   | -            |  
|Prepaid expenses                                                          |   | (2,083       | ) |   |              |  
|Accounts payable                                                          |   | 13,512       |   |   | (13,956      | )
|Net cash (used
      in) provided by operating activities from continuing |   | (130,985     | ) |   | 14,283       |  
|operations                                                                |   |              |   |   |              |  
|                                                                          |   |              |   |   |              |  
|Change in discontinued
      assets (liabilities)                         |   | 33,188       |   |   | (11,871      | )
|                                                                          |   |              |   |   |              |  
|Net cash (used in) provided
      by operating activities                 |   | (97,797      | ) |   | 2,412        |  
|                                                                          |   |              |   |   |              |  
|Cash flows used in investing
      activities                             |   |              |   |   |              |  
|Acquisition
      of HVPS                                                 |   | (50,000      | ) |   | -            |  
|                                                                          |   |              |   |   |              |  
|Cash flows provided by financing activities                               |   |              |   |   |              |  
|Issuance
      of common shares                                           |   | 171,080      |   |   | -            |  
|                                                                          |   |              |   |   |              |  
|Effect of exchange rate
      changes                                     |   | 969          |   |   | 847          |  
|                                                                          |   |              |   |   |              |  
|NET INCREASE IN CASH                                                      |   | 24,252       |   |   | 3,259        |  
|                                                                          |   |              |   |   |              |  
|CASH, BEGINNING OF YEAR                                                   |   | 10,943       |   |   | 7,684        |  
|                                                                          |   |              |   |   |              |  
|CASH, END OF YEAR                                                         | $ | 35,195       |   | $ | 10,943       |  
|                                                                          |   |              |   |   |              |  
|Supplemental Cash Flow Information                                        |   |              |   |   |              |  
|Cash paid during the year for:                                            |   |              |   |   |              |  
|Interest                                                                  | $ | -            |   | $ | -            |  
|Taxes                                                                     | $ | -            |   | $ | -            |  
|                                                                          |   |              |   |   |              |  
|Supplemental Non Cash Investing and Financing activities                  |   |              |   |   |              |  
|Assumption of accrued expenses upon acquisition
      of HVPS             | $ | 12,904       |   | $ | -            |  

F-7

---

EUOKO GROUP INC (formerly VITA EQUITY INC.) AND SUBSIDIARY
  
  NOTES TO CONSOLIDATED FINANCIAL STATEMENTSFOR THE YEARS ENDED DECEMBER 31, 2007 AND 2006

|NOTE 1 | SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
|------ | ------------------------------------------

Organization

Vita Equity Inc. was incorporated in
  the state of Nevada on July 25, 2000. Vita Equity Inc. acquired all of the outstanding
  common shares of Vita Equity Inc. (Canada) on September 20, 2000.

The Company was involved in the manufacture
  of custom ordered jewelry from precious metals and precious stones. On February
  27, 2007, the Company decided to discontinue its jewelry operations (see note
  3).

On March 16, 2007, our Board of Directors
  approved a 2.6 for 1 forward stock split of our authorized, issued and outstanding
  shares of common stock, effective March 22, 2007. As a result, our authorized
  capital increased from 50,000,000 shares of common stock with a par value of
  $0.001 to 130,000,000 shares of common stock with a par value of $0.001. Our
  issued and outstanding share capital increased from 13,200,000 to 34,372,000
  shares of common stock. The outstanding shares and per share calculations have
  been retroactively adjusted to effect the stock split as if it occurred at the
  beginning of the earliest period presented.

On April 5, 2007, the Company closed
  a private placement of 728,000 common shares at a purchase price of $0.235 per
  share for gross proceeds of $171,080 which increased outstanding share capital
  to 35,100,000.

On May 24, 2007, the Company merged
  with its wholly owned subsidiary, Euoko, Inc. On January 10, 2008, the Company
  changed its name to Euoko Group Inc.

On December 20, 2007, the Company completed
  the acquisition of Hewitt-Vevey Pharma Sciences Ltd. (HVPS) for $50,000. The
  acquisition was accounted for as a purchase in accordance with Statement of
  Financial Accounting Standards (SFAS) No. 141 Business Combinations
  and the assets acquired and liabilities assumed were recorded at their fair
  values at the date of acquisition (see Note 4).

On March 7, 2008, the Company acquired
  all of the outstanding shares of Euoko Inc. (Canada), a private Canadian company
  in exchange for $145,000 and 12,285,000 shares of preferred stock and as a result
  Euoko Inc. (Canada) became a wholly owned subsidiary of the Company. The acquisition
  will be accounted for as a reverse merger (recapitalization) with Euoko, Inc.
  (Canada) deemed to be the accounting acquirer, and the Company the legal acquirer.
  Commensurate with the transaction, the Company changed its year end to July
  31.

These financial statements represent
  only the results of Euoko Group Inc. prior to the reverse merger.

F-8

---

EUOKO GROUP INC (formerly VITA EQUITY INC.) AND SUBSIDIARY
  
  NOTES TO CONSOLIDATED FINANCIAL STATEMENTSFOR THE YEARS ENDED DECEMBER 31, 2007 AND 2006

Going Concern

The accompanying consolidated financial
  statements have been prepared in conformity with generally accepted accounting
  principles in the United States of America, which contemplates continuation
  of the Company as a going concern. The Company had a net loss of $133,593 for
  the year ended December 31, 2007 and as of December 31, 2007 the Company had
  an accumulated deficit of $147,381. The Company discontinued its jewelry operations
  business (see note 3). These matters raise substantial doubt about the Companys
  ability to continue as a going concern. Managements plan is to attempt
  to raise additional capital until such time the Company is able to generate
  sufficient operating revenue or complete a business combination or other such
  transaction. In view of these matters, realization of certain of the assets
  in the accompanying consolidated financial statements is dependent upon continued
  operation of the Company, which in turn is dependent upon the Companys
  ability to meet its financial requirements, raise additional capital, and the
  success of its future operations. Management believes that its ability to raise
  additional capital provides the opportunity for the Company to continue as a
  going concern. The Company has gone through a winding down of its operations,
  and the ability to continue as a going concern is dependent upon the addition
  of profitable operations and support from stockholders and investors.

Principles of consolidation

The consolidated financial statements
  include the accounts and operations of Euoko Group Inc. (formerly Vita Equity
  Inc.) and its wholly owned subsidiaries Vita Equity Inc. (Canada) and Hewitt-Vevey
  Pharma Sciences Ltd. Intercompany accounts and transactions have been eliminated
  in consolidation.

Use of estimates

The preparation of consolidated financial
  statements in conformity with accounting principles generally accepted in the
  United States of America requires management to make estimates and assumptions
  that affect the reported amounts of assets and liabilities and the disclosure
  of contingent assets and liabilities at the dates of the consolidated financial
  statements and the reported amounts of revenues and expenses during the reporting
  periods. Actual results could differ from those estimates.

Cash and Cash Equivalents 
  Cash and cash equivalents include cash on hand, amounts due to banks, and any
  other highly liquid investments with a maturity of three months or less. The
  carrying amounts approximate fair values because of the short-term maturity
  of those instruments.

Fair Value of Financial Instruments

The Companys financial instruments
  consist of sales taxes receivable, prepaid expenses, accounts payable and accrued
  liabilities and due to stockholder. The fair value of these financial instruments
  approximates their carrying amount given the short period to receipt or payment
  of cash. It is managements opinion that the Company is not exposed to
  any significant interest rate or credit risks arising from these financial instruments.

F-9

---

EUOKO GROUP INC (formerly VITA EQUITY INC.) AND SUBSIDIARY
  
  NOTES TO CONSOLIDATED FINANCIAL STATEMENTSFOR THE YEARS ENDED DECEMBER 31, 2007 AND 2006

Goodwill and other intangible assets

Goodwill represents the excess of the
  cost of the acquired entity over the net of amounts assigned to assets acquired
  and liabilities assumed, and it is not amortized. The Company tests goodwill
  for impairment at least annually by using a two-step process. In the first step,
  the fair value of the reporting unit, estimated using a discounted cash flows
  approach, is compared with the carrying amount of the reporting unit, including
  goodwill. If the carrying amount of the reporting unit exceeds its fair value,
  goodwill is considered impaired and a second step is performed to measure the
  amount of impairment loss, if any.

Income taxes

The Company accounts for income taxes
  under the asset and liability method. Under this method, deferred tax assets
  and liabilities are recognized and measured using enacted tax rates at the balance
  sheet date. Deferred tax expense or benefit is the result of changes in deferred
  tax assets and liabilities. Valuation allowances are established when necessary
  to reduce net deferred taxes to amounts that are more likely than not to be
  realized.

Earnings (loss) per common share

Net income (loss) per common share (basic
  and diluted) is based on the net income (loss) divided by the weighted average
  number of common shares outstanding during each year. Basic and diluted earnings
  per share are the same as the Company does not have any common stock equivalents
  or other potentially dilutive securities.

Foreign currency translation

Assets and liabilities of the foreign
  subsidiary are translated into U.S. dollars at period end exchange rates. Capital
  accounts are translated into U.S. dollars at the acquisition date rates. Income
  and expense items are translated at the weighted average exchange rates for
  the period. Net exchange gains or losses resulting from such translations are
  excluded from net income (loss) but are included in comprehensive income (loss)
  and accumulated in a separate component of stockholders' equity.

Comprehensive income (loss)

Comprehensive gain (loss) is defined
  to include all changes in equity except those resulting from investments by
  owners and distributions to owners. Among other disclosures, all items that
  are required to be recognized under current accounting standards as components
  of comprehensive gain (loss) should be reported in a financial statement that
  is presented with the same prominence as other financial statements.

The Company's only current component
  of comprehensive gain (loss) is a foreign currency translation adjustment. The
  foreign currency translation gains and losses resulting from the translation
  of the consolidated financial statements of the Company and its subsidiary expressed
  in Canadian dollars to United States dollars are reported as Accumulated Other
  Comprehensive Income in the accompanying Consolidated Statement of Stockholders
  Equity.

Other comprehensive income was $1,454
  and $847 for the years ended December 31, 2007 and 2006, respectively.

F-10

---

EUOKO GROUP INC (formerly VITA EQUITY INC.) AND SUBSIDIARY
  
  NOTES TO CONSOLIDATED FINANCIAL STATEMENTSFOR THE YEARS ENDED DECEMBER 31, 2007 AND 2006

Recent accounting pronouncements

In September 2006, the FASB issued SFAS
  No. 157, "Fair Value Measurements," which provides enhanced guidance for using
  fair value to measure assets and liabilities. SFAS No. 157 provides a common
  definition of fair value and establishes a framework to make the measurement
  of fair value in generally accepted accounting principles more consistent and
  comparable. SFAS No. 157 also requires expanded disclosures to provide information
  about the extent to which fair value is used to measure assets and liabilities,
  the methods and assumptions used to measure fair value, and the effect of fair
  value measures on earnings. SFAS No. 157 is effective for financial statements
  issued in fiscal years beginning after November 15, 2007 and to interim periods
  within those fiscal years.

In February 2007, the Financial Accounting
  Standards Board (FASB) issued SFAS Statement No. 159, The Fair Value Option
  for Financial Assets and Financial Liabilities - Including an amendment of FASB
  Statement No. 115 (SFAS 159). SFAS 159, which becomes effective for the
  Company on January 1, 2008, permits companies to choose to measure many financial
  instruments and certain other items at fair value and report unrealized gains
  and losses in earnings. Such accounting is optional and is generally to be applied
  instrument by instrument.

In December 2007, the FASB issued FASB
  Statement No. 141 (R), Business Combinations (FAS 141(R)), which
  establishes accounting principles and disclosure requirements for all transactions
  in which a company obtains control over another business. Statement 141 (R)
  applies prospectively to business combinations for which the acquisition date
  is on or after the beginning of the first annual reporting period beginning
  on or after December 15, 2008. Earlier adoption is prohibited.

In December 2007, the FASB issued SFAS
  No. 160, Non-controlling Interests in Consolidated Financial Statements,
  an amendment of ARB No. 51. SFAS No. 160 establishes accounting and reporting
  standards that require that the ownership interests in subsidiaries held by
  parties other than the parent be clearly identified, labeled, and presented
  in the consolidated statement of financial position within equity, but separate
  from the parents equity; the amount of consolidated net income attributable
  to the parent and to the non-controlling interest be clearly identified and
  presented on the face of the consolidated statement of income; and changes in
  a parents ownership interest while the parent retains its controlling
  financial interest in its subsidiary be accounted for consistently. SFAS No.
  160 also requires that any retained non-controlling equity investment in the
  former subsidiary be initially measured at fair value when a subsidiary is deconsolidated.
  SFAS No. 160 also sets forth the disclosure requirements to identify and distinguish
  between the interests of the parent and the interests of the non-controlling
  owners. SFAS No. 160 applies to all entities that prepare consolidated financial
  statements, except not-for-profit organizations, but will affect only those
  entities that have an outstanding non-controlling interest in one or more subsidiaries
  or that deconsolidate a subsidiary. SFAS No. 160 is effective for fiscal years,
  and interim periods within those fiscal years, beginning on or after December
  15, 2008. Earlier adoption is prohibited. SFAS No. 160 must be applied prospectively
  as of the beginning of the fiscal year in which it is initially applied, except
  for the presentation and disclosure requirements. The presentation and disclosure
  requirements are applied retrospectively for all periods presented.

The Company does not believe that the
  adoption of the above recent pronouncements will have a material effect on the
  Companys consolidated results of operations, financial position, or cash
  flows.

F-11

---

EUOKO GROUP INC (formerly VITA EQUITY INC.) AND SUBSIDIARY
  
  NOTES TO CONSOLIDATED FINANCIAL STATEMENTSFOR THE YEARS ENDED DECEMBER 31, 2007 AND 2006

Reclassifications

The Company has reclassified its 2006
  financial statements to reflect its jewelry business as discontinued operations.

|NOTE 2 | RELATED PARTY TRANSACTIONS
|------ | --------------------------

Related party transactions consist of
  the following:

Year EndedDecember 31,
      
      
      December 31,2007
      
      
      2006Sales
      $
      -
      
      $
      1,799,030Rent
      $
      2,095
      
      $
      7,935


Related party sales represent sales
  to Montecristo Jewelers Ltd., a Canadian company owned by a beneficial stockholder
  of the Company. At December 31, 2007 and 2006, $0 and $684,963, respectively,
  was due from this related party for sales on account.

The Company leases office space from
  CMMG Finance Inc., a company controlled and owned by Mr. Pasquale Cusano, who
  is also the beneficial owner of Montecristo Jewelers Ltd., and Nuvo Magazine
  Ltd., a beneficial stockholder of the Company. In October 2003, the Company
  renewed the lease which now requires monthly lease payments of $698. Included
  in accounts payable at December 31, 2007 and at December 31, 2006, was $0 and
  $0, respectively, due to this related party for rent.

Due to stockholder at December 31, 2007
  and December 31, 2006 totaled $17,441 and $17,441 respectively, is unsecured,
  non-interest bearing, with no fixed maturity date.

|NOTE 3 | DISCONTINUED OPERATIONS
|------ | -----------------------

On February 20, 2007, the Company decided
  to discontinue its jewelry operations as it was not sufficiently profitable
  and management had determined that prospects for the business were not good.
  Management is currently concentrating its efforts on pursuing a change of business
  for the Company. As such, the results of these operations have been reflected
  as discontinued operations in the accompanying statements of operations for
  the years ended December 31, 2007 and 2006.

For the year ended December 31, 2006,
  sales to Montecristo Jewelers, Ltd., a related party and Canadian customer,
  accounted for 99% of the sales. The Company had no sales during the year ended
  December 31, 2007. As of December 31, 2006, 98% of the Companys accounts
  receivable was from Montecristo Jewelers Ltd., a related party.

The Company purchased all of its precious
  metals from one vendor and its precious stones from various suppliers. Material
  precious metals purchased from one vendor aggregated 64% of the Companys
  total merchandise purchases for the year ended December 31, 2006. The Company
  made no material precious metals purchases for the year ended December 31, 2007.

F-12

---

EUOKO GROUP INC (formerly VITA EQUITY INC.) AND SUBSIDIARY
  
  NOTES TO CONSOLIDATED FINANCIAL STATEMENTSFOR THE YEARS ENDED DECEMBER 31, 2007 AND 2006

|NOTE 3 | DISCONTINUED OPERATIONScontinued
|------ | --------------------------------

Income (loss) from discontinued operations
  was as follows:

| |                                            |   | December 31, |   |   | December 31, |  
| | ------------------------------------------ | - | ------------ | - | - | ------------ | -
| |                                            |   | 2007         |   |   | 2006         |  
| |                                            |   |              |   |   |              |  
| | REVENUES:                                  |   |              |   |   |              |  
| | Trade                                      | $ | -            |   | $ | 12,300       |  
| | Related Party                              |   | -            |   |   | 1,799,030    |  
| | Total Revenue                              |   | -            |   |   | 1,811,330    |  
| |                                            |   |              |   |   |              |  
| | COST OF SALES                              |   | -            |   |   | (1,704,462   | )
| |                                            |   |              |   |   |              |  
| | GROSS PROFIT                               |   | -            |   |   | 106,868      |  
| |                                            |   |              |   |   |              |  
| | OPERATING EXPENSES                         |   |              |   |   |              |  
| | Professional fees                          |   | -            |   |   | 13,039       |  
| | Management salaries                        |   | -            |   |   | 35,268       |  
| | Rent                                       |   | -            |   |   | 7,935        |  
| | Consulting                                 |   | -            |   |   | 22,616       |  
| | Bad debt                                   |   | 8,605        |   |   | -            |  
| | Bank charges and interest                  |   | -            |   |   | 383          |  
| | Total Operating
      Expenses             |   | (8,605       | ) |   | 79,241       |  
| |                                            |   |              |   |   |              |  
| | (Loss) income from discontinued operations | $ | (8,605       | ) | $ | 27,627       |  

|NOTE 4 | ACQUISITION OF HEWITT-VEVEY PHARMA SCIENCES
      LTD.
|------ | ------------------------------------------------------

On December 20, 2007, the Company entered
  into a share purchase agreement with CMMG Finance Inc., a related party (see
  Note 2) to purchase all of the issued and outstanding shares of Hewitt-Vevey
  Pharma Sciences Ltd. (HVPS) a Canadian corporation. HVPS was incorporated
  on May 22, 2007 as White RX Laboratories Inc. under the laws of the Canada Business
  Corporation Act and began operations shortly thereafter. On October 15, 2007,
  White RX Laboratories Inc. changed its name to Hewitt-Vevey Pharma Sciences
  Ltd. HVPS is a developmental stage company that plans to research, develop,
  market and distribute scientifically advanced skin treatments.

Effective with the agreement, the Company
  purchased 100% of the issued and outstanding shares in the capital of HVPS for
  $50,000 and the assumption of $12,904 of liabilities. The Company will also
  pay a royalty fee calculated by multiplying 0.0275 by the gross revenues of
  HVPS within 60 days of each fiscal year-end of HVPS up to a maximum cumulative
  royalty fee of $500,000 USD.

F-13

---

EUOKO GROUP INC (formerly VITA EQUITY INC.) AND SUBSIDIARY
  
  NOTES TO CONSOLIDATED FINANCIAL STATEMENTSFOR THE YEARS ENDED DECEMBER 31, 2007 AND 2006

|NOTE 4 | ACQUISITION OF HEWITT-VEVEY PHARMA SCIENCES
      LTD.continued
|------ | ---------------------------------------------------------------

The acquisition of HVPS has been accounted
  for as a purchase in accordance with SFAS No. 141, Business Combinations,
  and the operations of the company have been consolidated commencing with the
  closing of the transaction. The purchase price was allocated to the assets acquired
  and liabilities assumed according to their estimated fair values at the date
  of acquisition as follows:

Purchase PriceCash consideration
      $
      50,000Purchase price allocationGoodwill
      $
      62,904Current liabilities
      
      (12,904
      )Total purchase price
      $
      50,000


The unaudited pro forma condensed consolidated
  statement of operations for the year ended December 31, 2007 presented below
  gives effect to the acquisition as if the transaction had occurred at the beginning
  of such period.

The Pro Forma Unaudited Financial Statements
  have been prepared by management of the Company in order to present results
  of operations of the Company and HVPS as if the acquisition had occurred at
  January 1, 2007.

| |                                                          |   | 2007     |  
| | -------------------------------------------------------- | - | -------- | -
| | Revenues                                                 | $ | -        |  
| | Operating expenses                                       |   | 137,519  |  
| | Loss from continuing operations                          |   | (137,519 | )
| | Loss from discontinued operations                        |   | (8,605   | )
| | Net loss                                                 |   | (146,124 | )
| | Other comprehensive income, foreign currency translation |   |          |  
| | adjustments                                              |   | 1,454    |  
| | Comprehensive loss                                       | $ | (144,670 | )

F-14

---

EUOKO GROUP INC (formerly VITA EQUITY INC.) AND SUBSIDIARY
  
  NOTES TO CONSOLIDATED FINANCIAL STATEMENTSFOR THE YEARS ENDED DECEMBER 31, 2007 AND 2006

|NOTE 5 | INCOME TAXES                                                                                 
|------ | ---------------------------------------------------------------------------------------------
|       |                                                                                              
|       | Significant components of the Companys deferred
      income tax assets at December 31, 2007
|       | and December 31, 2006 are as follows:                                                        

| |                               |   | December 31, |   |   | December 31, |  
| | ----------------------------- | - | ------------ | - | - | ------------ | -
| |                               |   | 2007         |   |   | 2006         |  
| | Deferred income tax asset:    |   |              |   |   |              |  
| | Net operating loss carry      | $ | 45,422       |   | $ | 185          |  
| | forward                       |   |              |   |   |              |  
| | Valuation allowance           |   | (45,422      | ) |   | (185         | )
| | Net deferred income tax asset | $ | -            |   | $ | -            |  

The Company, based upon its history
  of losses in the U.S. parent Company and managements assessment of when
  these operations are anticipated to generate taxable income, has concluded that
  it is more likely than not that none of the U.S. net deferred income tax assets
  will be realized through future taxable earnings and has established a valuation
  allowance for them.

Reconciliation of the effective income
  tax rate to the U.S and Canadian statutory rates are as follows:

| |                                  |  | Year Ended   |  
| | -------------------------------- |  | ------------ | -
| |                                  |  | December 31, |  
| |                                  |  | 2007         |  
| |                                  |  |              |  
| | Tax expense at the U.S.          |  |              |  
| | statutory income tax rate        |  | 34%          |  
| | (Utilization of) increase in the |  |              |  
| | valuation allowance              |  | (34%         | )
| | Effective income tax rate        |  | -            |  

Net operating loss carry forwards from
  U.S. operations totaling approximately $147,381 federal at December 31, 2007
  are being carried forward. The net operating loss carry forwards expire at various
  dates through 2027 for federal purposes.

Effective January 1, 2007, the Company
  adopted Financial Accounting Standards Board Interpretation No. 48, Accounting
  for Uncertainty in Income Taxes (FIN 48) an interpretation
  of FASB Statement No. 109, Accounting for Income Taxes. The Interpretation
  addresses the determination of whether tax benefits claimed or expected to be
  claimed on a tax return should be recorded in the financial statements. Under
  FIN 48, we may recognize the tax benefit from an uncertain tax position only
  if it is more likely than not that the tax position will be sustained on examination
  by the taxing authorities, based on the technical merits of the position. The
  tax benefits recognized in the financial statements from such a position should
  be measured based on the largest benefit that has a greater than fifty percent
  likelihood of being realized upon ultimate settlement. FIN 48 also provides
  guidance on derecognition, classification, interest and penalties on income
  taxes, accounting in interim periods and requires increased disclosures. At
  the date of adoption, and as of December 31, 2007, the Company does not have
  a liability for unrecognized tax benefits.

F-15

---

EUOKO GROUP INC (formerly VITA EQUITY INC.) AND SUBSIDIARY
  
  NOTES TO CONSOLIDATED FINANCIAL STATEMENTSFOR THE YEARS ENDED DECEMBER 31, 2007 AND 2006

|NOTE 5 | INCOME TAXEScontinued                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
|------ | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
|       | The Company files income tax
        returns in the U.S. federal jurisdiction. The Company is subject to U.S.
        federal income tax examinations by tax authorities for five years after
        2002. During the periods open to examination, the Company has net operating
        loss and tax credit carry forwards for U.S. federal tax purposes that
        have attributes from closed periods. Since these NOLs and tax credit carry
        forwards may be utilized in future periods, they remain subject to examination.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
|       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
|       | The Companys policy is
        to record interest and penalties on uncertain tax provisions as income
        tax expense. As of December 31, 2007, the Company has no accrued interest
        or penalties related to uncertain tax positions.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
|       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
|NOTE 6 | SUBSEQUENT EVENTS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
|       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
|       | On March 7, 2008, the Company
        acquired all of the outstanding shares of Euoko Inc. (Canada), a private
        Canadian company in exchange for $145,000 and 12,285,000 shares of preferred
        stock and as a result Euoko Inc. (Canada) became a wholly owned subsidiary
        of the Company. Each shareholder of outstanding shares of preferred stock
        is entitled to five hundred (500) votes for each share of preferred stock
        held on all matters submitted to a vote of shareholders. Cumulative voting
        is not provided for in the articles of incorporation or any amendments
        thereto, which means that the majority of votes can elect all of the directors
        then standing for election. Preferred stock is not entitled to preemptive
        rights and is not subject to conversion or redemption. Upon the occurrence
        of a liquidation, dissolution or winding-up, the holders of shares of
        preferred stock are not entitled to share ratably in all assets remaining
        after payment of liabilities and satisfaction of preferential rights of
        any outstanding preferred stock. There are no sinking fund provisions
        applicable to our preferred stock. The outstanding shares of our preferred
        stock are fully paid and non- assessable. The holders of outstanding shares
        of our preferred stock are not entitled to receive dividends out of assets
        legally available at times and in amounts as our board of directors may
        determine.
|       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
|       | The acquisition will be accounted
        for as a reverse merger (recapitalization) with Euoko, Inc. (Canada) deemed
        to be the accounting acquirer, and the Company the legal acquirer. Euoko
        Inc. (Canada) is engaged in the development, marketing and distribution
        of luxury skin treatments. The Company also granted options to purchase
        1,500,000 shares of common stock to the former shareholders of Euoko Inc.
        (Canada). The fair value of the options will be reflected as compensation
        expense on the date granted. The Company has also decided to change its
        year end to July 31 commensurate with the transaction.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

F-16

---

EUOKO GROUP INC (formerly VITA EQUITY INC.) AND SUBSIDIARY
  
  NOTES TO CONSOLIDATED FINANCIAL STATEMENTSFOR THE YEARS ENDED DECEMBER 31, 2007 AND 2006

|NOTE 6 | SUBSEQUENT EVENTScontinued                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
|------ | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
|       | On March 7, 2008, the Company
        entered into a loan payable to a shareholder of the Company, unsecured,
        interest at 1.25% per annum payable at maturity, due March 6, 2013. The
        loan agreement allows for the Company to borrow up to $1,150,000. Beginning
        February 1, 2008, in addition to interest, the Company must pay to the
        lender a royalty fee based on 8.75% of all gross revenues of Hewitt Vevey
        Pharma Sciences Ltd., payable annually. The royalty life is indefinite.

F-17

---

Item
8.           Changes In
and Disagreements With Accountants on Accounting and Financial Disclosure.

None

Item
8A.        Disclosure Controls and
Procedures

We maintain disclosure controls and procedures designed to
ensure that we are able to collect, process, summarize and disclose the
information we are required to disclose in the reports we file with the
Securities and Exchange Commission (SEC) within the time periods specified in
the applicable rules.

At the end of the period covered by this Annual Report on Form
10-KSB, our Chief Executive Officer (principal executive officer) and Chief
Financial Officer (principal financial officer) carried out an evaluation of the
effectiveness of the design and operation of our disclosure controls and
procedures as of December 31, 2007 (as defined in Rule 13a-15(e) promulgated
under the Securities and Exchange Act of 1934, as amended.) Based on that
evaluation, our principal executive officer and our principal financial officer
concluded that these controls and procedures are effective in timely alerting
them to material information relating to our company required to be included in
our periodic SEC filings. There has been no change in our internal control over
financial reporting during the recently completed fiscal period ended December
31, 2007 that has materially affected, or is reasonably likely to materially
affect, our internal control over financial reporting.

The term internal control over financial reporting is defined
as a process designed by, or under the supervision of, our principal executive
and our principal financial officer, or persons performing similar functions,
and effected by our board of directors, management and other personnel, to
provide reasonable assurance regarding the reliability of financial reporting
and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles and includes those policies and
procedures that:

|(a) | Pertain to the maintenance of records that in reasonable
      detail accurately and fairly reflect our transactions and dispositions of
      the assets;                                                                                                                                                                                    
|--- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|    |                                                                                                                                                                                                                                                                                                                                               
|(b) | Provide reasonable assurance that transactions are
      recorded as necessary to permit preparation of financial statements in
      accordance with generally accepted accounting principles, and that our
      receipts and expenditures are being made only in accordance with
      authorizations of our management and directors; and,
|    |                                                                                                                                                                                                                                                                                                                                               
|(c) | Provide reasonable assurance regarding prevention or
      timely detection of unauthorized acquisition, use or disposition of our
      assets that could have a material effect on the financial
    statements.                                                                                                                            

Management's Report on Internal Control over Financial
Reporting

Management of our company is responsible for establishing and
maintaining adequate internal control over financial reporting, as such term is
defined in the Securities Exchange Act Rule 13a-15(f). Our principal financial
officer conducted an evaluation of the effectiveness of our internal control
over financial reporting as of December 31, 2007 as required by the Securities
Exchange Act of 1934 Rule 13a-15(c). In making this assessment, our principal
financial officer used the criteria set forth in the framework in Internal
Control  Integrated Framework issued by the Committee of Sponsoring
Organizations of the Treadway Commission. Based on the evaluation conducted
under the framework in Internal Control  Integrated Framework. Our principal
financial officer concluded that our companys internal control over financial
reporting was effective, as of December 31, 2007, in providing reasonable
assurance regarding the reliability of financial reporting and the preparation
of financial statements for external purposes in accordance with generally
accepted accounting principles. However, our principle financial officer
concluded that there was a weakness in our internal control because no audit
committee had been established as of December 31, 2007.

This report does not include an attestation report of our
registered public accounting firm regarding internal control over financial
reporting. Managements report was not subject to attestation by our companys
registered public accounting firm pursuant to temporary rules of the SEC that
permit our company to provide only management's report in this Annual Report on
Form 10-KSB.

---

Item
8B.         Other Information

None.

PART III

Item
9.           Directors,
Executive Officers, Promoters and Control Persons; Compliance with Section 16(a)
of the Exchange Act.

Directors and Executive Officers, Promoters and Control
Persons

As at April 15, 2008, our directors and executive officers, their
  age, positions held, and duration of such, are as follows:

Name
      Position Held with our Company
      Age
      Served as aDirector and/or
      Officer of Euoko Inc. SinceBrandon Truaxe
    President, Chief Executive Officer and
      director
    29
    July 13, 2003*Michael Basler
    Chief Financial Officer,
      Secretary, Treasurer and director
    45
    July 27, 2007*Julio Torres
    Vice President and Chief
      Innovations Officer and director
    33
    October 19, 2005*


*Became an officer of Euoko Group Inc. on March 7, the date of
our acquisition of Euoko Inc., and became a director of Euoko Group Inc. on
April 14, 2008.

Business Experience

The following is a brief account of the education and business
experience of directors and executive officers during at least the past five
years, indicating their principal occupation during the period, and the name and
principal business of the organization by which they were employed.

Brandon Truaxe, President and Chief Executive Officer

Educated in Computer Science at the University of Waterloo,
Brandons interest in business development has allowed him to explore a variety
of successful ventures in software, nutrition, graphics design and cosmetics.
Having conceptualized and founded Euoko, Brandon has also maintained a
successful software development business, Custom Struct, whose most notable
project has been the leading of a renowned web-centric automotive financing
system for the Canadian operations of DealerTrack Holdings, Inc. This software
system has revolutionized online lending, and is used by more than 2,500
automotive dealerships and over twenty prime and sub-prime lending institutions.
Prior to founding Euoko, Inc., he was a founding member and president of
Schematte Corporation (a software development firm) and Organic Senses Ltd. (a
marketer of nutritional supplements). Brandon has developed and led Euokos
branding, design, ingredient selection, legal issues, website design, software
design and all aspects of Euokos business. Mr. Truaxe has no prior public
company experience as a director or officer.

Michael Basler, Chief Financial Officer

Michael Basler has an Honours B.A. (major in Economics) from
  Wilfrid Laurier University and received his Certified Management Accountant
  designation in 1992. For the past twenty years, Michael has held senior financial
  management positions of increasing responsibility with publicly-listed companies.
  Prior to joining Euoko in July 2007, Michael held the position of Chief Financial
  Officer with DealerTrack Canada Inc., a Canadian subsidiary of DealerTrack Holdings,
  Inc.

---

Prior to DealerTrack Canada Inc., he was Corporate Controller
  and Treasurer with Platform Technologies Inc., and Corporate Controller with
  both Teklogix International Inc. and Promis Systems Corporation. Michaels
  experience includes establishing and administratively staffing international
  subsidiary organizations, dealing with the complexities of international income
  and value-added tax regimes, tariffs and duties, and consolidated and local
  financial reporting. Michael was also instrumental in preparing each of the
  companies with which he has worked for their Initial Public Offerings. Mr. Basler
  has no public company experience as a director or officer.

Julio Torres, Vice President and Chief Innovations Officer

Educated in Computer Science at the University of Havana,
  Julio has gained extensive background in modern software development in positions
  of progressively increasing responsibility with Cubas Ministry of Finance.
  Prior to joining Euoko, Julio held the position of CEO at Vitral Projects Limited,
  a software firm founded by him that provided software consulting services to
  DealerTrack Holdings, Inc. His firm has collaborated extensively with Brandon
  Truaxe in the development of a complex automotive financing software system
  for DealerTrack. At Euoko, Julios creativity and extensive design background
  have allowed him to play a vital role since the early stages of the companys
  brand and image development. Euoko benefits not only from Julios creativity
  and extraordinary attention to detail, but also from his solid technology background
  which has been fundamental in the development of Euokos technology requirements.
  Julio has been heavily involved in the development of Euokos branding,
  design, formulation, ingredient selection, supplier selection, legal issues,
  website design, software design and all aspects of Euokos business. Mr.
  Torres has no public company experience as a director or officer.

Board Meetings and Committees

Our board of directors held no formal meetings during the
  12 month period ended December 31, 2007. All proceedings of the board of directors
  were conducted by resolutions consented to in writing by the directors and filed
  with the minutes of the proceedings of the directors. Such resolutions consented
  to in writing by the directors entitled to vote on that resolution at a meeting
  of the directors are, according to the Nevada Revised Statutes and the
  by-laws of our company, as valid and effective as if they had been passed at
  a meeting of the directors duly called and held.

We do not have standing audit, nominating or compensation
  committees, or committees performing similar functions. Our board of directors
  believes that it is not necessary to have standing audit, nominating or compensation
  committees at this time because the functions of such committees are adequately
  performed by our board of directors. The directors who perform the functions
  of auditing, nominating and compensation committees are not independent because
  they are also officers of our company. The determination of independence of
  directors has been made using the definition of independent director,
  as that term is used in Rule 4200(a)(15) of the of the Rules of NASDAQ Market
  Place Rules. There has not been any defined policy or procedure requirements
  for stockholders to submit recommendations or nomination for directors.

---

Our board of directors does not believe that a defined policy
  with regard to the consideration of candidates recommended by stockholders is
  necessary at this time because we believe that, given the early stages of our
  development, a specific nominating policy would be premature and of little assistance
  until our business operations are at a more advanced level. There are no specific,
  minimum qualifications that our board of directors believes must be met by a
  candidate recommended by our board of directors. The process of identifying
  and evaluating nominees for director typically begins with our board of directors
  soliciting professional firms with whom we have an existing business relationship,
  such as law firms, accounting firms or financial advisory firms, for suitable
  candidates to serve as directors. It is followed by our board of directors
  review of the candidates resumes and interview of candidates. Based on
  the information gathered, our board of directors then makes a decision on whether
  to recommend the candidates as nominees for director. We do not pay any fee
  to any third party or parties to identify or evaluate or assist in identifying
  or evaluating potential nominee.

Audit Committee Financial Expert

Our board of directors has determined that it does not have a
  member that qualifies as an “audit committee financial expert” as
  defined in Item 401(e) of Regulation S-B.

We believe that our entire board of directors is capable of
analyzing and evaluating financial statements that present a breadth and level
of complexity of accounting issues that are generally comparable to the breadth
and complexity of the issues reasonably expected to be raised by our company. In
addition, we believe that retaining an independent director who would qualify as
an audit committee financial expert would be overly costly and burdensome and
is not warranted in our circumstances given the early stages of our development.

Family Relationships

There are no family relationships between any director or
executive officer.

Involvement in Certain Legal Proceedings

Our sole director, executive officers, promoters or control
persons have not been involved in any of the following events during the past
five years:

1. any bankruptcy petition filed by or
against any business of which such person was a general partner or executive
officer either at the time of the bankruptcy or within two years prior to that
time;

2. any conviction in a criminal
proceeding or being subject to a pending criminal proceeding (excluding traffic
violations and other minor offences);

3. being subject to any order,
judgment, or decree, not subsequently reversed, suspended or vacated, of any
court of competent jurisdiction, permanently or temporarily enjoining, barring,
suspending or otherwise limiting his involvement in any type of business,
securities or banking activities; or

4. being found by a court of competent
jurisdiction (in a civil action), the Commission or the Commodity Futures
Trading Commission to have violated a federal or state securities or commodities
law, and the judgment has not been reversed, suspended, or vacated.

Code of Ethics

Effective April 14, 2007, our company's board of directors
adopted a Code of Business Conduct and Ethics that applies to, among other
persons, members of our board of directors, our company's officers including our
president (being our principal executive officer and principal financial
officer), contractors, consultants and advisors. As adopted, our Code of
Business Conduct and Ethics sets forth written standards that are designed to
deter wrongdoing and to promote:

|1. | honest and ethical conduct, including the ethical
      handling of actual or apparent conflicts of interest between personal and
      professional relationships;
|-- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------

---

|2. | full, fair, accurate, timely, and understandable
      disclosure in reports and documents that we file with, or submit to, the
      Securities and Exchange Commission and in other public communications made
      by us;
|-- | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|   |                                                                                                                                                                                                                              
|3. | compliance with applicable governmental laws, rules and
      regulations;                                                                                                                                                   
|   |                                                                                                                                                                                                                              
|4. | the prompt internal reporting of violations of the Code
      of Business Conduct and Ethics to an appropriate person or persons
      identified in the Code of Business Conduct and Ethics; and                            
|   |                                                                                                                                                                                                                              
|5. | accountability for adherence to the Code of Business
      Conduct and Ethics.                                                                                                                                               

Our Code of Business Conduct and Ethics requires, among other
things, that all of our company's personnel shall be accorded full access to our
president and secretary with respect to any matter which may arise relating to
the Code of Business Conduct and Ethics.

Further, all of our company's personnel are to be accorded full
access to our company's board of directors if any such matter involves an
alleged breach of the Code of Business Conduct and Ethics by our Company
officers. In addition, our Code of Business Conduct and Ethics emphasizes that
all employees, and particularly managers and/or supervisors, have a
responsibility for maintaining financial integrity within our company,
consistent with generally accepted accounting principles and federal and state
securities laws. Any employee who becomes aware of any incidents involving
financial or accounting manipulation or other irregularities, whether by
witnessing the incident or being told of it, must report it to his or her
immediate supervisor or to our company's president or secretary. If the incident
involves an alleged breach of the Code of Business Conduct and Ethics by the
president or secretary, the incident must be reported to any member of our board
of directors. Any failure to report such inappropriate or irregular conduct of
others is to be treated as a severe disciplinary matter. It is against our
company policy to retaliate against any individual who reports in good faith the
violation or potential violation of our company's Code of Business Conduct and
Ethics by another. We will provide a copy of the Code of Business Conduct and
Ethics to any person without charge, upon request. Requests may be sent in
writing to our company at Suite 314  837 West Hastings Street, Vancouver, BC,
V6C 3N6.

Section 16(a) Beneficial Ownership Compliance

Section 16(a) of the Securities Exchange Act requires our
executive officers and directors, and persons who own more than 10% of our
common stock, to file reports regarding ownership of, and transactions in, our
securities with the Securities and Exchange Commission and to provide us with
copies of those filings. Based solely on our review of the copies of such forms
received by us, or written representations from certain reporting persons, we
believe that during fiscal year ended December 31, 2007, all filing requirements
applicable to its officers, directors and greater than ten percent beneficial
owners were complied with, with the exception of the following:

Name
    Number of Late Reports
    Number of Transactions Not
      Reported on a Timely Basis
    Failure to File Requested FormsBrandon Truaxe
    1(1)
    1
    N/A


|(1) | The named officer, director or greater than 10%
      stockholder, as applicable, filed a late Form 3  Initial Statement of
      Beneficial Ownership.
|--- | --------------------------------------------------------------------------------------------------------------------------------------------------------

Item
10.         Executive Compensation.

The particulars of compensation paid to the following persons:

- our principal executive officer;

---

- each of our two most highly compensated executive officers who were serving
  as executive officers at the end of the year ended December 31, 2007 who had
  total compensation exceeding $100,000; and
- up to two additional individuals for whom disclosure would have been provided
      but for the fact that the individual was not serving as our executive officer
      at the end of the most recently completed financial year, who we will collectively
      refer to as the named executive officers, of our years ended December 31,
      2007, 2006 and 2005, are set out in the following summary compensation table:

SUMMARY COMPENSATION TABLEName and 
        principal 
        position
      Year
      Salary ($)
      Bonus 
        ($)
      Stock 
        Awards 
        ($)
      Option 
        Awards 
        ($)
      Non-Equity  Incentive Plan 
        Compensation 
        ($)
      Nonqualified  Deferred 
        Compensation 
        Earnings ($)
      All Other 
        Compensation 
        ($)
      Total ($)Brandon Truaxe, 
        President & CEO(1)
      2007 
        2006 
        2005
      30,000 CD(7)
        Nil 
        Nil
      Nil 
        Nil 
        Nil
      Nil 
        Nil 
        Nil
      Nil 
        Nil 
        Nil
      Nil 
        Nil 
        Nil
      Nil 
        Nil 
        Nil
      Nil 
        Nil 
        Nil
      30,000 CD(7)
        Nil 
        NilMichael Basler, 
        CFO, Secretary 
        and Treasurer (2)
      2007 
        2006
        2005
      54,295CD
        Nil 
        Nil
      15,625 CD(3)
        Nil 
        Nil
      Nil 
        Nil 
        Nil
      Nil 
        Nil 
        Nil
      Nil 
        Nil 
        Nil
      Nil 
        Nil 
        Nil
      15 CD
        Nil 
        Nil
      69,935CD
        Nil 
        NilJulio Torres, 
        Vice President and 
        Chief Innovations 
        Officer(4)
      2007 
        2006 
        2005
      Nil 
        Nil 
        Nil
      Nil 
        Nil 
        Nil
      Nil 
        Nil 
        Nil
      Nil 
        Nil 
        Nil
      Nil 
        Nil 
        Nil
      Nil 
        Nil 
        Nil
      Nil 
        Nil 
        Nil
      Nil 
        Nil 
        NilMauro Baessato(5)
      2007 
        2006 
        2005
      Nil 
        Nil 
        Nil
      Nil 
        Nil 
        Nil
      Nil 
        Nil 
        Nil
      Nil 
        Nil 
        Nil
      Nil 
        Nil 
        Nil
      Nil 
        Nil 
        Nil
      Nil 
        Nil 
        Nil
      Nil 
        Nil 
        NilDwight Webb, 
        Director (6)
      2007 
        2006 
        2005
      Nil
        35,268 
        Nil
      Nil 
        Nil 
        Nil
      Nil 
        Nil 
        Nil
      Nil 
        Nil 
        Nil
      Nil 
        Nil 
        Nil
      Nil 
        Nil 
        Nil
      Nil 
        Nil 
        Nil
      Nil
        35,268 
        Nil


| | (1) | Brandon Truaxe became an Officer and Director of Euoko
        Inc. on July 13, 2003 and an officer of Euoko Group Inc. on March 7, 2008.                                                                           
| | --- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
| |     |                                                                                                                                                                                                                     
| | (2) | Michael Basler became an Officer and Director of Euoko
        Inc. on July 27, 2007 and an officer of Euoko Group Inc. on March 7, 2008.                                                                           
| |     |                                                                                                                                                                                                                     
| | (3) | Accrued but not yet paid.                                                                                                                                                                                           
| |     |                                                                                                                                                                                                                     
| | (4) | Julio Torres became an Officer and Director of Euoko
        Inc. on October 19, 2005 and an officer of Euoko Group Inc. on March 7,
        2008.                                                                  
| |     |                                                                                                                                                                                                                     
| | (5) | Mauro Baessato became an Officer and Director on August
        1, 2000 and resigned from the position of Director on April 13, 2003.
        Mauro Baessato resigned as an officer of our company on March 7, 2008.
| |     |                                                                                                                                                                                                                     
| | (6) | Dwight Webb became an Officer and Director on August
        1, 2000 and resigned as an officer on March 7, 2008 and as a director
        on April 14, 2008.                                                       
| |     |                                                                                                                                                                                                                     
| | (7) | Accrued but not yet paid.                                                                                                                                                                                           

*Compensation of Directors*

We reimburse our directors for expenses incurred in connection
with attending board meetings. We have not paid any director's fees or other
cash compensation for services rendered as a director since our inception to
December 31, 2007.

We have no formal plan for compensating our directors for their
  service in their capacity as directors, although such directors are expected
  in the future to receive stock options to purchase common shares as awarded
  by our board of directors or (as to future stock options) a compensation committee
  which may be established. Directors are entitled to reimbursement for reasonable
  travel and other out-of-pocket expenses incurred in connection with attendance
  at meetings of our board of directors. Our board of directors may award special
  remuneration to any director undertaking any special services on our behalf
  other than services ordinarily required of a director. No director received
  and/or accrued any compensation for their services as a director, including
  committee participation and/or special assignments.

---

Long-Term Incentive Plans

There are no arrangements or plans in which we provide pension,
retirement or similar benefits for directors or executive officers, except that
our directors and executive officers may receive stock options at the discretion
of our board of directors. We do not have any material bonus or profit sharing
plans pursuant to which cash or non-cash compensation is or may be paid to our
directors or executive officers, except that stock options may be granted at the
discretion of our board of directors.

We have no plans or arrangements in respect of remuneration
received or that may be received by our executive officers to compensate such
officers in the event of termination of employment (as a result of resignation,
retirement, change of control) or a change of responsibilities following a
change of control, where the value of such compensation exceeds $60,000 per
executive officer.

Item
11.         Security Ownership of
Certain Beneficial Owners and Management.

As of April 14, 2008, there were 35,100,000 shares of our
common stock and 12,285,000 shares of our preferred stock issued and
outstanding. The following table sets forth certain information known to us with
respect to the beneficial ownership of our common stock as of that date by (i)
each of our directors, (ii) each of our executive officers, and (iii) all of our
directors and executive officers as a group. Except as set forth in the table
below, there is no person known to us who beneficially owns more than 5% of our
common stock. The number of shares beneficially owned is determined under rules
of the Securities and Exchange Commission and the information is not necessarily
indicative of beneficial ownership for any other purpose. Under such rules,
beneficial ownership includes any shares as to which the individual has the sole
or shared voting power or investment power and any shares which the individual
has the right to acquire within 60 days of April 14, 2008 through the exercise
of any stock option or other right. Unless otherwise noted, we believe that each
person has sole investment and voting power (or shares such powers with his or
her spouse) with respect to the shares set forth in the following table:

Name and Addressof Beneficial Owner(1)
      Title of Class
      Amount and Nature ofBeneficial Owner
      Percent of Class(1)(2)Brandon Truaxe, President &
      CEO
    Preferred Stock
    12,285,000
    100%Common Stock
    10,704,000(3)
    30%Julio Torres Vice President and Chief
      Innovations Office
    Common Stock
    1,955,000(4)
    6%Michael Basler, CFO, Secretary &
      Treasurer
    Common Stock
    325,000(5)
    *Directors and Officersas a group
    Preferred Stock
    12,285,000
    100%Common Stock
    12,984,000(6)
    36%(6)


|(1) | Based on 35,100,000 shares of common stock and 12,285,000
      shares of preferred stock issued and outstanding as of April 14, 2008 and
      as of the date of this annual report on Form 10-KSB. Except as otherwise
      indicated, we believe that the beneficial owners of the common stock
      listed above, based on information furnished by such owners, have sole
      investment and voting power with respect to such shares, subject to
      community property laws where applicable. Beneficial ownership is
      determined in accordance with the rules of the Securities and Exchange
      Commission and generally includes voting or investment power with respect
      to securities. Shares of common stock subject to options or warrants
      currently exercisable or exercisable within 60 days are deemed outstanding
      for the purposes of computing the percentage ownership of the person
      holding such options or warrants, but are not deemed outstanding for the
      purposes of computing the percentage ownership of any other
  person.
|--- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

---

|(2) | Since each of our preferred shares carries the right
        to vote 500 times per preferred share, this means that, counting both
        his preferred shares and common shares, Brandon Truaxe controls 6,153,004,000
        votes out of a possible 6,177,600,000 votes, which is approximately 99.6%
        of the total possible votes in a vote by our shareholders concerning the
        management of our company.
|--- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|    |                                                                                                                                                                                                                                                                                                                                                                                                                               
|(3) | Includes 10,504,000 common shares and 200,000 common
      share purchase options issued on March 7, 2008, pursuant to the amended
      and restated share exchange agreement with Euoko, at an exercise price of
      $1.00 and an expiry date of March 7, 2013.                                                                                                                                                           
|    |                                                                                                                                                                                                                                                                                                                                                                                                                               
|(4) | Includes 1,755,000 common shares and 200,000 common share
      purchase options issued on March 7, 2008.                                                                                                                                                                                                                                                                                                                     
|    |                                                                                                                                                                                                                                                                                                                                                                                                                               
|(5) | Includes 325,000 common share purchase options issued on
      March 7, 2008.                                                                                                                                                                                                                                                                                                                                                 
|    |                                                                                                                                                                                                                                                                                                                                                                                                                               
|(6) | Together, Brandon Truaxe and Julio Torres control
      6,154,759,000 shareholder votes, which is approximately 99.6% of the
      possible votes in a vote by our shareholders.                                                                                                                                                                                                                                              

Changes in Control

A change in control of our company occurred as a result of the
share exchange we completed with the former shareholders of Euoko Inc. on March
7, 2008.

As a result of the share exchange, one former shareholder of
Euoko Inc., Brandon Truaxe, now owns 12,285,000 preferred shares in our company.
Each preferred share carries with it the voting rights of 500 votes per share.
So, the 12,285,000 preferred shares now held by Brandon Truaxe have the power of
6,142,500,000 votes. Two of the three former shareholders of Euoko, Inc.,
Brandon Truaxe and Julio Torres have purchased 10,504,000 common shares and
1,755,000 of our common shares, respectively, from some of our shareholders on
their own.

We have 35,100,000 shares of our common stock, par value
$0.001, issued and outstanding. Each common share carries with it the voting
rights of one (1) vote per share.

This means that Brandon Truaxe controls 6,153,004,000 votes out
of a possible 6,177,600,000 votes, which is approximately 99.6% of the total
possible votes in a vote by our shareholders, concerning the management of our
company. Together, Brandon Truaxe and Julio Torres control 6,154,759,000
shareholder votes, which is approximately 99.6% of the possible votes in a vote
by our shareholders.

Our former control person, Dwight Webb, our sole director, now
owns 1,475,000 shares of our common stock, constituting approximately 4% of our
issued and outstanding common stock. Dwight Webb now has 1,475,000 votes, which
represents less than 1% of the possible 6,177,600,000 votes in a vote by our
shareholders.

The issuance of the 12,285,000 preferred shares effectively gives
  the control of the management and direction of our company to Brandon Truaxe,
  who is also now our President and Chief Executive Officer.

Furthermore Brandon Truaxe holds 200,000 common stock options,
Julio Torres holds 200,000 common stock options and Michael Basler holds 325,000
common stock options. These options can be exercised for one common share each
at a price of $1.00 until they expire on March 7, 2013 or until they are
terminated pursuant to other terms and conditions of the option agreements, the
form of which is attached as an exhibit to this current report.

Item
12.         Certain Relationships
and Related Transactions.

Except as disclosed herein, there have been no transactions or
proposed transactions in which the amount involved exceeds the lesser of
$120,000 or one percent of the average of our total assets at year-end for the
last three completed fiscal years in which any of our directors, executive
officers or beneficial holders of more than 5% of the outstanding shares of our
common stock, or any of their respective relatives, spouses, associates or
affiliates, has had or will have any direct or material indirect interest.

On March 7, 2008, we completed a share exchange involving,
among others, Brandon Truaxe, the beneficial shareholder of approximately 30% of
our issued and outstanding common shares and Julio Torres, the beneficial
shareholder of approximately 5% of our issued and outstanding common stock.

---

The share exchange was with the former shareholders of Euoko
Inc.: Brandon C. Truaxe; Julio Alexis Torres Lopez; and, CMMG Finance Inc.
Through this share exchange, we acquired all of the issued and outstanding
shares of Euoko Inc., a private Canadian company engaged in the business of the
development, marketing and distribution of luxury skin treatments.

In consideration for the shares of Euoko Inc. that we received,
we paid at total of $145,000, issued 12,285,000 preferred shares to the former
shareholders of Euoko Inc. and granted 1,500,000 common stock options to Brandon
Truaxe, Michael Basler and Julio Torres as well as eleven other optionees named
by Brandon Truaxe and Julio Torres. We paid the consideration as follows:

to Brandon Truaxe, $28,000, 12,285,000
preferred shares and 200,000 common stock options;

to CMMG Finance, $110,000;

to Julio Torres, $7,000 and 200,000
common stock options;

to Michael Basler 325,000 common stock
options; and,

to named Optionees, 775,000 common
stock options.

As a result of the share exchange, Brandon Truaxe, now owns
12,285,000 preferred shares in our company. Each preferred share carries with it
the voting rights of 500 votes per share. The 12,285,000 preferred shares carry
the voting power of 6,142,500,000 common shares. We have 35,100,000 shares of
our common stock, par value $0.001, issued and outstanding. Each common share
carries with it the voting rights of one (1) vote per share. The completion of
the share exchange, including the issuance of the 12,285,000 preferred shares,
effectively gives the control of the management and direction of our company to
Brandon Truaxe, who is also now our President and Chief Executive Officer.

Also pursuant to the share exchange, Julio Torres is now our
Vice President and Chief Innovations Officer and Michael Basler is now our Chief
Financial Officer, Secretary and Treasurer.

The approximate dollar value of the transaction was $740,785.
This was an exchange of shares plus some additional consideration, the amounts
of which were negotiated between the parties and arrived at as the fair value of
the rights and interests being exchanged. This transaction was reviewed,
approved and ratified by our sole director.

Review, Approval or Ratification of Transactions with
Related Parties

Other than the Company's Code of Ethics, the Board does not
have a specific written policy regarding the review, approval or ratification of
transactions with related parties. Our board of directors does, however, follow
certain procedures relating to the approval of transactions involving related
parties. Related parties generally include executive officers and directors,
stockholders owning more than 5% of our common stock or immediate family members
of any such persons. A related party transaction will be approved only if it is
disclosed to our board of directors and is approved by a majority of the
disinterested members of our board of directors. Prior to approving any related
party transaction, our board of directors reviewing such transaction must (i) be
satisfied that they received all material facts relating to the transaction,
(ii) have considered all relevant facts and circumstances available to them and
(iii) have determined that the transaction is in (or not inconsistent with) the
best interests of our companys shareholders. No director that is an interested
party in a transaction may participate in the approval of such transaction.

---

Item
13.         Exhibits

Exhibits required by Item 601 of Regulation S-B

|Exhibit | Description                                                                                                                                                                                                                                                            
|------- | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|Number  |                                                                                                                                                                                                                                                                        
|        |                                                                                                                                                                                                                                                                        
|(3)     | (i) Articles of Incorporation; and (ii) Bylaws                                                                                                                                                                                                                         
|        |                                                                                                                                                                                                                                                                        
|3.1     | Articles of Incorporation (incorporated by reference from
      our Form SB-2 filed on September 21, 2004).                                                                                                                                                            
|        |                                                                                                                                                                                                                                                                        
|3.2     | Bylaws (incorporated by reference from our Form SB-2
      filed on September 21, 2004).                                                                                                                                                                               
|        |                                                                                                                                                                                                                                                                        
|3.3     | Certificate of Change filed with the Secretary of State
      of Nevada on March 22, 2007 (incorporated by reference from our Current
      Report on Form 8-K filed on March 22, 2007).                                                                               
|        |                                                                                                                                                                                                                                                                        
|3.4     | Certificate of Correction filed with the Secretary of
      State of State of Nevada on March 19, 2007 (incorporated by reference from
      our Current Report on Form 8-K filed on March 22, 2007)                                                                   
|        |                                                                                                                                                                                                                                                                        
|3.5     | Articles of Merger filed with the Secretary of State of
      Nevada on May 17, 2007 and which is effective May 24, 2007 (incorporated
      by reference from our Current Report on Form 8-K filed on May 25, 2007)                                                   
|        |                                                                                                                                                                                                                                                                        
|3.6     | Certificate of Amendment to Articles of Incorporation
      filed with the Nevada Secretary of State on June 22, 2007 (incorporated by
      reference from our Current Report on form 8-K filed on June 28, 2007)                                                     
|        |                                                                                                                                                                                                                                                                        
|3.7     | Articles of Merger filed and effective with the Secretary
      of State on January 10, 2008 (incorporated by reference from our Current
      Report of Form 8-K filed on January 22, 2008)                                                                           
|        |                                                                                                                                                                                                                                                                        
|(10)    | Material Contracts                                                                                                                                                                                                                                                     
|        |                                                                                                                                                                                                                                                                        
|10.1    | Assignment and Assumption Agreement (incorporated by
      reference from our Form SB-2 filed on September 21, 2004).                                                                                                                                                  
|        |                                                                                                                                                                                                                                                                        
|10.2    | Declaration of Trust (incorporated by reference from our
      Form SB-2 filed on September 21, 2004).                                                                                                                                                                 
|        |                                                                                                                                                                                                                                                                        
|10.3    | Letter Agreement dated April 5, 2007 (incorporated by
      reference from our Current Report on Form 8-K filed on April 25, 2007).                                                                                                                                    
|        |                                                                                                                                                                                                                                                                        
|10.4    | Amended and Restated Share Exchange Agreement
      (incorporated by reference from our Current Report on Form 8-K filed on
      July 27, 2007)                                                                                                                       
|        |                                                                                                                                                                                                                                                                        
|10.5    | Share Purchase Agreement between Euoko Inc. and CMMG
      Finance Inc. (incorporated by reference form our Current Report on Form
      8-K filed on December 26, 2007)                                                                                               
|        |                                                                                                                                                                                                                                                                        
|10.6    | Letter from our company to Brandon Truaxe, Julio Torres
      and CMMG Finance Inc. to the Amended and Restated Share Purchase Agreement
      dated November 23, 2007 (incorporated by reference form our Current Report
      on Form 8-K filed on December 26, 2007)
|        |                                                                                                                                                                                                                                                                        
|10.7    | Loan Agreement (incorporated by reference from our
      Current Report on Form 8-K filed on March 13, 2008).                                                                                                                                                          
|        |                                                                                                                                                                                                                                                                        
|10.8    | Form of Option Agreement (incorporated by reference from
      our Current Report on Form 8-K filed on March 13, 2008).                                                                                                                                                
|        |                                                                                                                                                                                                                                                                        
|10.9    | Lease Agreement (incorporated by reference from our
      Current Report on Form 8-K filed on March 13, 2008).                                                                                                                                                         

---

|Exhibit | Description                                                                                                                                                                                                                
|------- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|Number  |                                                                                                                                                                                                                            
|        |                                                                                                                                                                                                                            
|10.10   | Employment agreement
        with Brandon Truaxe (incorporated by reference from our Current Report
        on Form 8-K filed on March 13, 2008).                                                                          
|        |                                                                                                                                                                                                                            
|10.11   | Employment agreement
        with Michael Basler (incorporated by reference from our Current Report
        on Form 8-K filed on March 13, 2008).                                                                          
|        |                                                                                                                                                                                                                            
|10.12   | Share Purchase
        Agreement between Euoko Inc. and CMMG Finance, Inc. (incorporated by reference
        from our Current Report on Form 8-K filed on December 26, 2007).                                             
|        |                                                                                                                                                                                                                            
|10.13   | Letter between
        the Parties to the Amended and Restated Share Purchase Agreement dated
        November 23, 2007 (incorporated by reference from our Current Report on
        Form 8-K filed on December 26, 2007).
|        |                                                                                                                                                                                                                            
|10.14   | Share Purchase
        Agreement between Euoko Inc. and CMMG Finance, Inc. (incorporated by reference
        from our Current Report on Form 8-K filed on December 26, 2007).                                             
|        |                                                                                                                                                                                                                            
|10.15*  | Term Loan Agreement dated April
      14, 2008.                                                                                                                                                                            
|        |                                                                                                                                                                                                                            
|(14)    | Code of Ethics                                                                                                                                                                                                             
|        |                                                                                                                                                                                                                            
|14.1    | Code of Business
        Conduct and Ethics (incorporated by reference from our Annual Report on
        Form 10- KSB filed on April 14, 2004).                                                                            
|        |                                                                                                                                                                                                                            
|(31)    | Rule 13a-14(a)/15d-14(a)
        Certifications                                                                                                                                                                            
|        |                                                                                                                                                                                                                            
|31.1*   | Section
        302 Certification under Sarbanes-Oxley Act of 2002 (Brandon Truaxe)                                                                                                                                        
|        |                                                                                                                                                                                                                            
|31.2*   | Section
        302 Certification under Sarbanes-Oxley Act of 2002 (Michael Basler)                                                                                                                                        
|        |                                                                                                                                                                                                                            
|(32)    | Section 1350
        Certifications                                                                                                                                                                                        
|        |                                                                                                                                                                                                                            
|32.1*   | Section
        906 Certification under Sarbanes-Oxley Act of 2002 (Brandon Truaxe)                                                                                                                                        
|        |                                                                                                                                                                                                                            
|32.2*   | Section
        906 Certification under Sarbanes-Oxley Act of 2002 (Michael Basler)                                                                                                                                        

*Filed herewith

Item
14.         Principal Accountant
Fees and Services

The following table sets forth the fees billed to the Company
for professional services rendered by the Company's independent registered
public accounting firm, for the years ended December 31, 2007 and December 31,
2006:

|Services       | 2007    | 2006   
|-------------- | ------- | -------
|Audit fees     | $21,596 | $22,390
|Tax fees       | $Nil    | $Nil   
|All other fees | $Nil    | $Nil   
|               |         |        
|Total fees     | $21,596 | $22,390

Audit Fees. Consist of fees billed for professional services
  rendered for the audits of our financial statements, reviews of our interim
  consolidated financial statements included in quarterly reports, services performed
  in connection with filings with the Securities and Exchange Commission and related
  comfort letters and other services that are normally provided by Weinberg &
  Company P.A. for the fiscal years ended December 31, 2007 and December 31, 2006
  in connection with statutory and regulatory filings or engagements.

---

Tax Fees. Consist of fees billed for professional
services for tax compliance, tax advice and tax planning. These services include
assistance regarding federal, state and local tax compliance and consultation in
connection with various transactions and acquisitions.

All Other Fees. We do not use Weinberg & Company P.A.,
  for financial information system design and implementation. These services,
  which include designing or implementing a system that aggregates source data
  underlying the financial statements or generates information that is significant
  to our financial statements, are provided internally or by other service providers.
  We do not engage Weinberg & Company P.A. to provide compliance outsourcing
  services.

Effective May 6, 2003, the Securities and Exchange Commission
  adopted rules that require that before Weinberg & Company P.A. is engaged
  by us to render any auditing or permitted non-audit related service, the engagement
  be:

- approved by our audit committee (the functions of which are performed by
  our entire board of directors); or
- entered into pursuant to pre-approval policies and procedures established
  by the board of directors, provided the policies and procedures are detailed
  as to the particular service, the board of directors is informed of each
  service, and such policies and procedures do not include delegation of the
  board of directors' responsibilities to management.

Our entire board of directors pre-approves all services
provided by our independent auditors. All of the above services and fees were
reviewed and approved by our sole director either before or after the respective
services were rendered.

Our board of directors have considered the nature and amount
  of fees billed by Weinberg & Company P.A. and believe that the provision
  of services for activities unrelated to the audit is compatible with maintaining
  Weinberg & Company P.A.’s independence.

---

SIGNATURES

In accordance with Section 13 or 15(d) of the Exchange Act, the
registrant caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.

| | EUOKO GROUP INC.
| | ----------------
| |                 
| |                 
| |                 
| | By:             
| |                 
| |                 
| |                 
| |                 
| | EUOKO GROUP INC.
| |                 
| |                 
| |                 
| | By:             
| |                 
| |                 
| |                 
| |                 



In accordance with the Exchange Act, this report has been
signed below by the following persons on behalf of the registrant and in the
capacities and on the dates indicated.



| | By: | /s/
      Brandon Truaxe                                
| | --- | --------------------------------------------------------
| |     | Brandon Truaxe, President and Chief Executive           
| |     | Officer (Principal Executive Officer)                   
| |     | Date: April 15, 2008                                    
| |     |                                                         
| |     |                                                         
| |     |                                                         
| | By: | /s/
      Michael Basler                                
| |     | Michael Basler, Chief Financial Officer                 
| |     | (Principal Financial Officer, Principal
      Accounting
| |     | Officer)                                                
| |     | Date: April 15, 2008                                    
| |     |                                                         
| |     |                                                         
| | By: | /s/
      Julio Torres                                  
| |     | Julio Torres, Director                                  
| |     | Date: April 15, 2008                                    

---